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Abstract
Background and Objective: Crohn’s disease (CD)-related complications account for a
substantial proportion of IBD-related healthcare expenditure. Identifying patients at risk
for complications may allow for targeted use of early therapeutic interventions to alter
this natural course. The objective of this project was to develop risk prediction models of
CD-related surgery and complications.
Methods: Using data from the REACT cluster-randomized clinical trial (N=1898 from 41
community practices), predictionmodelswere developed and internally validated for CD-
related surgery andCD-related complications, defined as the first CD-related surgery, hos-
pitalization or complication within 24 months. Performance of each model was assessed
in terms of discrimination and calibration, as well as decision curves and net benefit anal-
yses.
Results: There were 130 (6.8%) CD-related surgeries and 504 (26.6%) CD-related compli-
cations during the 24-month follow-up period. Selected baseline predictors for predicting
surgery included age, gender, disease location, HBI score, stool frequency, antimetabolite
or 5-aminosalicylates use, and the presence of a fistula, abscess or abdominal mass. Se-
lected predictors of complications included those same factors for surgery, corticosteroid
and TNF-antagonist use and excluded 5-aminosalicylate use. The discrimination ability,
asmeasured by optimism-corrected c-statistic, was 0.70 for the surgerymodel, and 0.62 for
the complication model. Score charts and nomograms were developed to facilitate future
risk score calculation.
Conclusions: Risk prediction models for CD-related surgery and CD-related complica-
tionswere developed using clinical trial data involving community gastroenterology prac-
tices. These models need to be externally validated before being used to guide manage-
ment of CD.
Keywords: prognostic model, Crohn’s disease, surgery, complications, risk estimate
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1Chapter 1
Introduction to prediction models
1.1 Introduction
This thesis concerns the development of prediction models for the risk of Crohn’s dis-
ease (CD)-related surgery and CD-related complications. Crohn’s disease is an idiopathic
disorder of the gastrointestinal tract characterized by chronic, segmental inflammation.
While the symptoms of CD typically flare up between periods of remission, many pa-
tients will have persistent sub-clinical inflammation of the bowel despite the use of main-
tenance drug therapy [1]. This inflammatory process predisposes patients to complica-
tions of stricture and fistula formation. Eventually, surgery will be required for up to 80%
of patients [2]. These complications may also recur. Surgery is also a risk factor for disease
recurrence [3, 4] and future disability [5, 6]. Thus, surgery is a clinically relevant outcome
to patients.
The objective of this thesis is to develop separate models for predicting the risk that a
patient will experience either a CD-related surgery and CD-related complications within
the proceeding two years of follow up.
2This chapter provides a review, within the context of CD, of the general methodology
to develop and validate clinical prediction models.
1.2 Crohn’s disease
Crohn’s disease is one of the twomajor subtypes of inflammatory bowel disease (IBD),
along with ulcerative colitis. Crohn’s disease is characterized by periods of active inflam-
mation and symptom flare ups that are separated by periods of quiescence or low disease
activity. Typical symptoms experienced in CD include abdominal pain and cramping,
(frequent) diarrhea, blood in the stool, fever, fatigue, reduced appetite and weight loss.
The inflammation in Crohn’s disease is transmural, affecting the entire thickness of the
intestinal wall, and even in asymptomatic periods, subclinical transmural inflammation
may persist.
1.3 What are prediction models?
Over the past decade, approximately 3,000 to 4,000 clinical prediction models (some-
times called clinical prediction rules, clinical decision rules or prediction models) have
been described in the biomedical literature based on a search of PubMed for the MeSH
heading "clinical prediction model." A prediction model can be used to assign a patient
an expected risk of receiving a particular diagnosis or prognosis or suggest a therapeu-
tic or diagnostic course of action. One of the most well-known prediction models is the
Framingham Heart Study coronary heart disease risk model, which predicts the ten-year
risk of developing heart disease [7]. An example of a decision prediction rule is the Ot-
tawa Angle Rule which determines whether a patient should undergo radiography for
ankle injuries [8]. The ultimate goal of the prediction model is to inform decisions about
patient care. When existing data are not available from which to develop a prediction
3model, they must be collected from a study specific to this task, such a retrospective chart
review, prospective cohort or even a clinical trial. If data are to be collected from a pro-
posed new study, this collection of patient data (especially from tests and procedures) can
be expensive. Therefore, it is essential that prediction models be well developed and fully
validated.
Development of prediction models is especially useful to guide patient care towards
the goal of personalized medicine. With personalized medicine, an algorithm (or model)
has the ability to risk stratify a patient and appropriately tailor their subsequent therapy.
Personalized medicine in IBD currently plays a limited role [9]. A clinician may identify
those patients at high risk of rapid progression to a complication and then must select,
monitor and adapt the most appropriate therapeutic strategies in order to achieve an ap-
propriate endpoint for that patient. Numerous clinical, genetic and immunological items
have already been identified as significant prognostic factors, to be discussed in the next
chapter. However, these have generally demonstrated heterogeneous prognostic ability in
prospective studies. Part of this variability is due to the choice of endpoint: a symptom-
based endpoint, a target disease activity score, or mucosal healing and deep remission.
The former is significantly limited by its poor association with objective markers of in-
flammation [10]. While the latter is still debated as being the optimal endpoint of healing
and resolution of inflammation, clinical trials of anti-TNF and anti-integrin biologic agents
have achieved mucosal healing and durable remission [11–17]. Mucosal healing is asso-
ciated with lower rates of inflammation, requirement of lower cumulative dose of corti-
costeroids and lower rates of both intestinal surgery and hospitalization [18, 19]. Mucosal
healing appears to be the more objective and reliable treatment target for IBD.
Using disease-based activity scores, those patients with low clinical activity may still
experience sub-clinical inflammation. Thus, theymay be under-treated and face increased
risk of progression tomore complicated disease behaviour or development of related com-
plications. If mucosal healing is the target endpoint, then a subset of patients without
clinical symptoms, but who have failed to reach endoscopic remission, would require es-
4calation to more intensive or effective therapies. However, this strategy may impose un-
necessary over-treatment for some. Whatever the choice of endpoint, a well-constructed
and validated prediction model can be a key part of risk stratifying patients while aiding
the clinician’s judgment with a patient’s predicted risk.
The development of a risk prediction model may proceed in four general steps: model
development, internal validation, external validation and optional model updating. Mul-
tivariable logistic regression models are usually constructed for predicting binary out-
comes while proportional hazard regression models are commonly used for predicting
the time to an event. The remainder of this section is a summary of the consensus ap-
proach to developing and validating prediction models that has been advocated for in the
biostatistics literature [20–25].
1.4 Model development
Before expending the effort to develop a model, the authors must ask themselves if
this model will be used, and who are the potential users. While there are thousands of
examples of prediction models in the biomedical literature, most of them have failed to
be translated into clinical settings. Models fail for various reasons, such as those listed by
Reilly et al. [26] and Laupacus et al. [27]. Important obstacles to application include: (1)
the potential users did not trust the variables, relationships or weights used in the model;
(2) the variables necessary to make predictions would not be routinely available; or (3) the
setting envisioned by the author for prediction is not relevant. If the authors deem the
modelling task to be worthwhile, the question arises of where and how to obtain the data.
51.4.1 Data collection and study design
A prospective cohort study can be designed for the specific purpose to develop a pre-
diction model. This may even be considered ideal, since the study can be designed with
an adequate sample size in order to estimate measures of discrimination or calibration
with pre-specified precision. The study could also be designed to recruit patients with
respect to a common temporal reference point, such as the onset of disease or time since
diagnosis. For instance, one could recruit newly diagnosed patients in order to predict
risks in early disease. Another advantage to the prospective design is the specificity to
the distribution of disease severity. For example, the prediction model may be intended
to predict risk in those with severe disease. Additionally, one could ensure enrollment for
specific covariate patterns, such as stratifying on age or gender. Here then, the prediction
model may be intended to have adequate power to make predictions in both elderly and
young males and females.
When it is too expensive or prohibitive to design a purpose-driven prospective study,
authorswill naturally obtain a convenience sample, such as frompatient chart reviews. This
approach is likely to present several issues, such as: missing clinically important variables;
lacking consensus (or operational) definitions of predictors or outcomes; poorly defined
patient populations; biases of retrospective data collection; large degrees of missing vari-
ables (especially when data are not missing at random); lack of standardized data collec-
tion methods and observer/rater variability. Several of these limitations can be avoided
by careful collection of data from prospective studies, including randomized trials, for the
deliberate purpose of developing prediction models. Though the data used in this thesis
were obtained from a controlled trial, this was not the primary purpose of the trial, though
we used this data nevertheless.
When seeking a convenient dataset to use, randomized controlled trials offer many
advantages over data obtained from cohort studies. Major strengths of such studies in-
clude: prospective design and data collection; standardized and stringent criteria for par-
6ticipant selection; objective outcome and variable definitions; and close follow up of study
participants. For all of its potential advantages, a trial may have limited generalizability,
especially when restrictive inclusion and exclusion criteria are applied, and may also be
limited when the trial is pragmatic in design [28, 29]. One simple example to see this is to
consider that many trials automatically exclude children and pregnant women for ethical
reasons. Once the data source has been chosen, the next concern is to select predictors.
1.4.2 Selection of potential predictors
Typical candidate predictors include: patient characteristics (age and sex are generally
included at a minimum), presence of co-morbidities, disease severity and laboratory or
diagnostic test results. Since the sample size and the number of events are (often) limited,
the variables must be selected judiciously to include only the most relevant predictors.
In contrast to etiologic study designs, the choice of predictors need not be causal, but
rather only associated with the outcome of interest. Even non-causal variables can be
highly predictive of an outcome [24]. Having chosen the predictors is itself claiming an
association between the predictor and the target outcome, while the specific modelling
procedure will assign a weight of “importance,” or strength of association.
It has been argued that as much information as possible should be extracted from
the variables [30]. Where one has the choice between categorizing a continuous variable
or keeping it continuous, the continuous case is preferred. Categorization of continuous
variables has been recognized as a practice that is relatively less statistically efficient and
encourages potentially arbitrary, data-driven choice of a cut point and increasing the risk
of attaining biased results [31–33]. If categorization is to be performed, then the loss of
information resulting from categorization must be weighed against the bias introduced
due to violating the assumptions of the relationship between the continuous predictor
and the outcome (e.g., the linear relationship between the continuous predictor and the
logit of risk). In the simple case, if the continuous predictor is dichotomized, it implies
7that the risk is constant within categories and that there is a discontinuous jump in risk
across categories. This may or may not be reasonable assumption to make.
It may be necessary to exclude predictors that are difficult to measure. The predictor
may be too expensive or too infrequently measured. It may be unavailable to the target
user. Or the variable may be more subjective to measure and have high inter-rater vari-
ability. A standardized and accurate measurement is necessary to enhance the predictive
ability of the model and its applicability [30].
Sample size considerations are an important issue in any research project. In the frame-
work of hypothesis testing and inferential statistics, a formal calculation or simulation of
sample size is a fundamental aspect of such empirical studies. These calculations are done
to meet a target amount of power for a statistical test at a pre-specified type I error rate
(alpha). Sample size estimation may also be done to ensure a target variance or width of a
confidence interval and ensure a desired level of precision. Formal sample size estimation
in prediction modeling is complicated due primarily to the fact that one needs to consider
multiple target statistics which each describe different aspects of the model performance,
such as discrimination and calibration. The literature has not yet reached a consensus on
which of these statistics is most important for calculation of sample size. As a result, most
researchers have turned to simulations and have instead used the idea of events per vari-
able (EPV) in order to compare the relative precision of a discrimination and calibration
statistics. For logistic and Cox proportional hazards models, the widely accepted rule-of-
thumb for the minimum number of events and non-events per variable can be as few as 10
EPV to more than 50 EPV [34–36], though there are some situations in which less than 10
EPV are acceptable [37]. The greater the EPV, the smaller the risk of bias in estimating the
model coefficients and hence more accurate model performance.
There are several methods which may be used to select predictors. Predictor selec-
tion should be informed by prior domain knowledge. Selecting appropriate predictors
will signal to the target users that the model could be sensible, prima facie. Solely relying
on statistically significant predictor-outcome relationships from univariate analyses risks
8potentially severe model bias and erroneously including predictors by chance [20, 21, 38,
39]. It has been recommended to use a backward selection procedure in combination with
bootstrap resampling shrinking estimated regression coefficients to correct for over-fitting
[21]. If there are multiple candidate predictors that the authors wish to include, but lim-
ited data, a commonly used strategy is to combine multiple related variables into a single
(summary) variable.
1.4.3 Outcome of interest
Any outcome may be predicted in principle. However, in the clinical prediction con-
text the authors should decide on an important outcome that is relevant to either the pa-
tient or clinician. The outcome should have an objective definition, or failing that, a stan-
dardized operational definition (e.g., presence or absence of a disease; a specific type of
surgical procedure; 30-day mortality). When given a choice, using a standardized, ob-
jective outcome (e.g., 30-day mortality, surgery by one year) is preferable to a broad or
subjective definition (e.g., need for treatment escalation or a composite of many different
specific outcomes). For example, a subjective outcome may be the decision of whether
there was inadequate response to treatment as judged by a clinician. Or an outcome that
defines need for treatment escalation that actually reflectsmany implicit decisions, includ-
ing physician experience, patient preference, hospital policies and treatment guidelines,
all of which are likely to vary between centres, geographic regions and maybe even across
time periods. Subjective outcomes increase the possibility of introducingmany biases due
to detection and assessment of the outcome, selection bias (e.g., the investigator may de-
cide the outcome definition was not reached for a particular patient due to their own per-
sonal bias), and recall bias if the outcome cannot be evaluated prospectively [40]. Using
standardized, objective definitions along with standardized measurements and blinded
outcome assessment is more in keeping with the PICOTS approach to risk of bias assess-
ment [41], in which every effort is made to assess the choice of outcome for risk of bias.
91.4.4 Modelling
Manymodelling strategies exist, such as non-parametric (rank-based), data-driven ap-
proaches, Bayesian models, and other statistical learning approaches. This thesis will
adopt and focus solely on a regression modeling approach. Details of regression mod-
elling have been extensively discussed in the literature [21].
1.5 Characterizing model performance
Model performance can be quantified using multiple measures [22, 42, 43]. First, cal-
ibration measures estimate the agreement between observed and predicted outcome fre-
quencies (or risks). Second, discrimination measures estimate the ability of the model
to distinguish between patients with different outcomes (e.g., distinguishing the diseased
from the non-diseased). Third, overall performancemeasures are thosewhich incorporate
some aspects of both calibration and discrimination. Eachmeasure assesses a different as-
pect of performance. For instance, calibration measures are more sensitive to systematic
deviations from predicted risks, whereas discrimination is better at detecting differences
in case-mix. Lastly, clinical usefulness (or utility) of the model must be assessed to de-
termine whether the model provides additional benefit to the clinical user. Both discrim-
ination and calibration are critical to interpreting the potential usefulness of the model
and they must be reported [25]. However, multiple measures of performance are recom-
mended to fully describe prediction models [25] and the most important are summarized
in Table 1.1.
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Table 1.1. Measures of prediction model validity and performance.
Aspect Measure Characteristics
Calibration Calibration plot Visual representation of agreement be-
tween observed and predicted probabilities
Calibration slope quantifies the agreement between pre-
dicted and observed outcome
Calibration inter-
cept (“calibration in
the large”)
Degree of systematic bias of predicted
probabilities (too high or too low)
Hosmer-Lemeshow
statistic
Degree of goodness-of-fit
Discrimination Concordance (c-
statistic); area under
ROC curve
Overall quality of predicted outcomes
across all possible risk thresholds; overall
agreement in predicted risks when ranking
a pair of patients, each with a different
outcome.
Boxplot of predicted
probabilities
Visual representation of spread of pre-
dicted probabilities for each outcome value
Discrimination
slope
Mean squared difference in predicted prob-
abilities between those with the outcome
and those without the outcome
Overall Brier score A measure of the error of the prediction
R2 Proportion of outcome variation that can be
explained by the model
Clinical utility Sensitivity Percentage of patients with the outcome
correctly classified as having the outcome
(requires selection
of risk threshold)
Specificity Percentage of patients without the outcome
correctly classified as not having the out-
come
Net benefit (NB) Model and reference policy are compared
using a weighting for the relative costs of
false-positive and false-negative classifica-
tion to determine the net number of true-
positive decisions gained for a single risk
threshold.
Decision curve anal-
ysis
Same as NB, but for a range of risk thresh-
olds.
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1.5.1 Discrimination measures
One way to quantify discrimination is to use Harrell’s concordance index (also called
the c-index or c-statistic) [44]. It quantifies the ability of the model to differentiate (dis-
criminate) between patients having different outcomes of interest. Among all pairs of pa-
tients with different outcomes, the c-statistic is concordance percentage when the higher
predicted risk of the pair correctly corresponds to having the outcome and the lower risk
corresponds to not having the outcome. Thus, the c-statistic is the probability across all
patients that a model will correctly predict that one high-risk patient has a higher prob-
ability of the outcome than another low-risk patient. In logistic regression models, the
c-statistic is equal to the area under the receiver operating characteristic curve [45]. A dis-
crimination value of 0.5 corresponds to predictions that are equally as good as chance (i.e.,
flipping a fair coin). A useful observed value should therefore be judged in the range from
0.5 to 1.0, the higher the better. Since it is based on the rank of predicted probabilities, this
measure cannot distinguish a pair of patients with probabilities of 0.1 and 0.11 with that
of 0.1 and 0.99.
1.5.2 Calibration measures
Calibration is a complementary performance measure to discrimination, quantifying
the agreement between the predicted and observed outcome. For example, if a predicted
risk is 10%, then (approximately) 10% of patients should have the outcome. Calibration
has commonly been assessed using the Hosmer-Lemeshow goodness-of-fit test. However,
the value of the test statistic, and thus a test of significantly poor calibration, varies greatly
when the number of groups are even slightly changed (say 8 or 9 groups compared to 10
groups) and has been reported to have low statistical power to detect meaningful miscal-
ibration [46].
Calibration may be assessed graphically using a calibration plot, with the predictions
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on the x-axis and the observations on the y-axis. If a model has perfect calibration, then
the resulting points of the calibration curve should all lie in a diagonal line coincidingwith
the 45° line. Deviations from perfect calibration result in an imperfect curve. Most often
when developing a model, over-fitting (optimism) will occur and yield a calibration curve
that is skewed to extreme predictions (slope <1); the predicted risk for low-risk patients
will be too low and for high-risk patients too high. The calibration curve is also useful to
detect if the model predicts risks that are systematically biased (too high or too low) and
this is captured by the calibration curve intercept and is sometimes called “calibration-in-
the-large”.
A model may be calibrated to varying degrees of robustness. Recently, Van Calster
and colleagues have proposed a hierarchy of calibration [47]. In the preceding paragraph,
a calibration curve approach corresponds to “moderate calibration” while the systematic
bias (“calibration-in-the-large”) corresponds to “weak calibration”. The strongest form of
calibration, according to their hierarchy, would be to check calibration for each and every
possible covariate pattern implied by the model. While this may be possible with only a
few binary predictors, they note that this is an impossible taskwhen continuous predictors
are present. Instead, model development and validation efforts should focus onmoderate
calibration [47].
1.5.3 Overall performance measures
It is also possible to compute measures which estimate both calibration and discrim-
inative ability into a single summary measure. The Brier score was derived for binary
outcomes [48] as a measure of the error of the prediction. For an example with actual out-
come Y and predicted probability p, the Brier score is [B = Y × (1− ¯ˆp1)2+(1−Y )× ¯ˆp20) =∑N
i=1(Yi − pˆi)2]. In other words, the Brier score computes the sum of the mean squared
difference between each predicted and observed outcome. It may be decomposed into cal-
ibration and discrimination [49, 50]. Sensible models have a Brier score that ranges from 0
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to 0.25; a perfectly calibrated and discriminating model has no prediction error and thus
a Brier score of 0, whereas a model that performs no better than chance has a score of
0.25 with an outcome prevalence of 50%. Because the Brier score is difficult to interpret,
a scaled Brier score can be calculated in which the scaled Brier ranges from 0% to 100%.
This is done by estimating the maximum Brier score under the assumption that the model
is non-informative [Bscaled = 1 − (B/Bmax);Bmax = mean(p) × (1 −mean(p))]. Similar to
the Brier score are the R2 measures of explained variance. Nagelkerke’s R2 is commonly
computed for generalized linear models [51]. For binary outcomes, Nagelkerke’s R2 is a
logarithm score of predicted probabilities [R2 = Y ×ln ( ¯ˆp1)+(Y −1)×(ln (1− ¯ˆp0))]. Nagelk-
erke’s R2 is interpretable as the proportion of outcome variation that can be explained by
the model’s predictors.
1.5.4 Clinical utility and net benefit
A model is useful in a clinical setting only if it can help a clinician to make a deci-
sion, such as order a test or initiate a treatment. Even if calibration and discrimination
ability are satisfactory for a group of patients, the decisions implied by the current guide-
lines (or policy) and by the model may be the same. Thus, the model does (not) perform
better than current guidelines and the model has (no) additional usefulness to the clini-
cian. This may be especially true when guidelines and policy documents already factor in
clinical variables into decision algorithms. Traditional measures of classification based on
contingency tables (i.e., sensitivity, specificity, positive predictive value, negative predic-
tive value) are already well known to clinicians. However, the clinical relevance of these
measures greatly depend on the relative benefit and costs of correctly classifying disease
(true-positive prediction) versus false classifications (specifically, false-positive and false-
negative predictions).
The clinical net benefit index is means of assessing the potential decisions made by
using the model by explicitly accounting for the clinical consequences of false-positive
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and false-negative diagnoses [52, 53]. The net benefit may be calculated by choosing risk
threshold at which point we would be indifferent to delivering a treatment to a patient
or not. For the calculation, this risk threshold is converted to odds, as in (pt/(1 − pt)). At
this specific threshold, the absolute number of true positives and false positives (TP and
FP , respectively) are computed over all patients (N ), and the net benefit is calculated as
NB = (TP/N) − (FP/N) × (pt/(1 − pt)). For example, if we assume that each benefit
gained by a true positive diagnosis is worth the harms realized by three false positives,
then it implies an odds of 1:3 or a risk threshold of 25%. By definition then, the net benefit
is exactly zero when the assumed costs (or harms) of false positive diagnoses are exactly
matched to the benefits of true positive diagnoses. By repeating this process over a range of
risk thresholds, a decision curve can be constructed to inspect and compare clinical utility
over a range of operating risk thresholds. Since the unit for net benefit is the number of
true cases found per patient, its maximum value is therefore defined at the prevalence. In
other words, its maximum is when all true cases are found, with no false positives. The
net benefit is directly interpretable as the rate of additional true-positive classifications
made at a specific risk threshold when using the model over an existing policy. It can also
be used to calculate the unnecessary interventions avoided.
When evaluating decision curves, they should at least be compared to two default
strategies in which either all patients are classified as positive (the treat all strategy) or
no patients are classified as positive (the treat none strategy). In the treat none strategy,
since no positive diagnoses are ever made, the net benefit is always exactly zero for any
risk threshold. In contrast, for the treat all strategy, all of the true positives are correctly
classified, and everyone else is by definition a false positive. In other words, the true
positive rate (TP/N ) represents the event rate and the false positive rate (FP/N ) represents
its complement (1 - event rate). Thus, the net benefit under a treat all strategy is exactly
zero when the threshold is equal to the event rate in order to satisfy this condition. Also
under the treat all strategy, the net benefit is maximized at the event rate when the risk
threshold is set to 0%.
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1.6 Internal validation
Everymodel is prone to over-fitting (optimism)which inevitably results in predictions
that are too extreme, especially when the number of events is small relative to the num-
ber of predictors [20, 21]. Once the candidate model has been decided, internal validation
is conducted to ascertain the best-fitted, most stable version of the model [20, 21]. It is
necessary that any prediction model study include some form of internal validation tech-
nique, which uses only the original study sample (development data), to quantify initial
optimism.
Internal validation requires some form of resampling technique, but may also involve
some (or all) of the model development steps. A popular method is split-sample testing in
which the data are randomly divided into a development subset and test subset (e.g., a 70-
30 split). Unless the dataset contains many (say 20,000) events of interest, this split-sample
approach is relatively statistically inefficient because some data are withheld. In a large
data set, this is not very concerning because the advantage is that the test performance in
the hold out data gives a clean estimate of performance without having seen the data and
the analyst being biased by multiple comparisons and exploratory analyses; however, in
small data sets which are common in the biomedical literature, holding out data increases
the risk of producing biased effect estimates [35, 54–56].
Cross-validation and bootstrap resampling are the two preferred methods of assess-
ing internal validity by means of computing model performance [20, 21, 24, 57]. Cross-
validation is a technique to validate predictive performance by randomly splitting the data
into a training set to estimate (train) the model and a hold out set to evaluate the model
[58]. In k-fold cross-validation, the dataset is randomly divided into equal subsamples of
size k. One of the k subsamples is held out, and the model is estimated using the remain-
ing k − 1 subsamples. The estimate of performance may be improved by repeating the
entire k-fold cross-validation procedure several times (say 100 to 200 times) and averaging
the desired performance result [21]. In contrast to data splitting, the principle underlying
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the bootstrap is to use resampling. One bootstrap sample requires drawing random sam-
ples of observations with replacement in order to create a new dataset of equal size to the
original dataset. Model performance can be estimated in this bootstrap sample, and the
statistic saved. This process is repeatedmany times (say 500 to 2000 times), each time com-
puting the same performancemeasure each bootstrap sample. At the end of the iterations,
the bootstrap performance measures are averaged for an estimate of model performance
[59]. The approach used in this thesis was to implement Efron’s optimism bootstrap to
characterize the degree of over-fitting [59] because it mimics the empirical distribution of
samples as if one were drawing random samples from the theoretical source population.
This bootstrap method naturally yields an estimate of the average amount of optimism in
initial regression coefficients and also in measures of model performance, which may be
adjusted accordingly [20, 21]. The initial (original) performance may be compared to the
performance measured using either cross-validation or bootstrap resampling, to estimate
the degree of optimism present in the original model building process.
It is also possible to use shrinkage techniques to reduce or remove this initial over-
fitting. These methods diminish coefficients toward zero in order to reduce error in risk
prediction for new individuals [60]. The shrinkage process implies a process of regression
to the mean, in which future predictions lie closer to the overall mean than might be ex-
pected from the original predicted value [61]. Shrinkage methods reduce over-fitting and
thereby improve model calibration [38, 62]. Several shrinkage techniques exist. The first
and simplest is applied after a regression model has been fit by using a common shrink-
age factor to reduce all coefficients by a fixed amount. This method is compatible with
bootstrapping techniques to estimate the degree of shrinkage required [21]. Penalized re-
gression is a more rigorous approach to estimating model coefficients, rather than apply-
ing shrinkage followingmodel fitting. The least absolute shrinkage and selection operator
(LASSO) and ridge regression are popular penalization methods and are also considered
within the TRIPOD statement for clinical models [25]. LASSO applies a constraint that
the sum of all p absolute model coefficients must remain smaller than some value, such
that |∑pj=1 |βj| | < c. In contrast, the constraint applied in penalized regression is to min-
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imize the sum of squared model coefficients,
∑p
j=1 β
2
j < c. The constraint value may be
estimated by cross-validation. The LASSO also incorporates shrinkage into variable selec-
tion, and works within logistic and Cox proportional hazards regression models [63–65].
Penalized maximum likelihood, a generalization of ridge regression, may also be used
with these models [66, 67]. Penalization methods are an active area of research in their
application to clinical models. While penalization methods are outside the scope of this
thesis, such methods are promising for model development using datasets with few ob-
servations or when there are many more potential predictors than available observations
(e.g., bioinformatic predictions) [68, 69].
1.7 External validation
Before a model can be used for clinical decision making, it is crucial to perform ex-
ternal validation. This process involves using completely new dataset with information
on the same predictors and outcome. Several forms of external validation may be consid-
ered, including: (1) prospective validation of a model developed retrospectively; (2) temporal
validation using the same cohort definition at two different time periods; (3) geographic val-
idation using cohorts from two independent locales; or (4) multi-centre validation. Some
authors have arranged these types of external validation into a hierarchy which is charac-
terized by increasing stringency and generalizability [70, 71].
Prospective validation requires a collecting data on a prospectively defined cohort.
Ideally all variables will also be assessed prospectively and in an unbiased manner. Pros-
pective validation is necessary for models developed using a retrospectively-defined co-
hort. Temporal validation is by definition a formof prospective validation. When this form
of validation is chosen, it may be a useful alternative to a split-sample internal validation
approach. If the rate of collection of new observations is reasonably fast, then it provides a
reasonable way to externally validate the model. However, some view this approach as a
disadvantage since it may be argued that if one could simply wait for more observations,
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then one should do so in order to build the model using more information. One clear
disadvantage is when outcomes are rare or concern time-to-event outcomes, where it will
necessarily take a long time to acquire an adequate cohort for validation. Alternatively,
prospective and temporal validation are useful to assess whether the same predictors are
still useful andwhether the estimate coefficients (such as their magnitude or direction) are
still compatible with theory and clinical expertise. However, neither prospective or tem-
poral validation address the wider generalizability of the model since they are derived
from cohorts within the same centre(s) and setting. Geographic and multi-centre valida-
tion are more stringent forms of assessing the wider external validity of a model. The
difference is whether data are collected from one or multiple independent centres and
gives a more realistic perspective on whether accuracy is maintained in these different
cohorts and different locales.
Formal sample size estimation is rarely done in practice for external validation studies.
It is recommended that at least 100 events of interest (and ideally >200 events) be included
in validation cohorts [72, 73]. These sample sizes are attainable from clinical trial datasets
or from large, population registries (such as insurance databases or national data clear-
inghouses), though rare outcomes present greater costs to data collection.
The process of external validation is very similar to that of internal validation. The
developed model and its coefficients are used on the new cohort to compute estimated
risks. Validation cohort performance is especially emphasized as this directly relates to
how the model can realistically perform. Ideally, the performance in the development
and validation cohorts will be similar, suggesting that the model will generalize to the
source populations of both. However, it is unsurprising to observe a (usually small) per-
formance loss upon external validation. Currently there are no strict guidelines to denote
poor or acceptable or very good performance [26, 70, 71, 74]. Authors will describe per-
formance as “acceptable”, “good”, or “excellent” without theoretical basis for such qual-
ifiers. Rather,these qualifiers are often chosen arbitrarily based on the context of other
models in the same or a related research discipline. If validated performance is lacking,
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the model may be updated by adjusting baseline risk or regression coefficients, or adding
or removing predictors [21]. If model updating is performed, it should technically then
be externally validated on the basis that this is now a new model and hence untested [28,
75].
An important step beyond external validation would be to determine the impact or
effectiveness of using the model. This should be done in the context of randomized con-
trolled trial, in which the patient is randomized or using a clustered design (e.g., random-
izing the clinician or the practice) [75]. Such a trial would demonstrate, in a controlled
way, that patient care is truly improved using the algorithm compared to usual care. Such
a design can also be adapted to include economic impacts of treatment decisions providing
an economic impact analysis, especially when associated treatments or diagnostic testing
is expensive or resource intensive.
1.8 Thesis scope and organization
The primary purpose of this thesis is to develop and internally validate risk predic-
tion models for CD-related complications, defined as hospitalization, surgery or serious
disease complication. The data were obtained from the Randomized Evaluation of an
Algorithm for Crohn’s Treatment (REACT) multi-centre, open-label, cluster-randomized
controlled trial [76]. REACT is one of the largest clinical trials in CD, and evaluated an
early, combined immunomodulation therapy algorithm for patients with CD in the com-
munity clinics compared to conventional care.
The remaining thesis chapters are organized as follows. Chapter 2will review impor-
tant clinical predictors associatedwith disease-related complicationswhich have informed
variable selection in the model development stage. Chapter 3 will focus on development
and validation of the prediction models using data from REACT. Chapter 4 will present
general conclusions and discuss further work.
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Chapter 2
Predictors in Crohn’s disease
2.1 Introduction
Crohn’s disease (CD) is idiopathic in nature and there is an extensive literature in epi-
demiology to identify potential factors associatedwith its onset and its complications. This
chapter reviews themost important prognostic factors associatedwith disease-related out-
comes. The first major consensus on risk factors of the disease course arose from the Vi-
enna classification in 1998 and its Montréal update [77, 78], in which a set of criteria were
created to stratify patients by disease phenotype and classify risk of disease progression
based on characteristics at diagnosis (Table 2.1).
InTable 2.1, age at diagnosis refers towhen positive clinical diagnosiswas established.
Disease location refers to the largest anatomic extension of the disease in any period prior
to the first surgery. There are four possible locations: terminal ileum (the inferior third of
the small intestinewith orwithout involvement of the cecum); colon (any location between
the cecum and the rectum); ileocolic (terminal ileumdisease and any place between the as-
cending colon and the rectum); and upper gastrointestinal tract (any location proximal to
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the terminal ileum). In the Montréal classification, L4 may modify any of the L1-L3 clas-
sifications. The behaviour phenotype may be either inflammatory (non-stricturing and
non-penetrating), stricturing or penetrating with an additional modifier of perianal dis-
ease. Stricturing disease is defined by the occurrence of constant stricture of the lumen
demonstrated by either radiology, endoscopy or surgery without evidence of penetration.
However, penetrating disease is defined by any occurrence of abdominal or perianal fistu-
las, inflammatory masses, and abscesses during any period of disease evolution. Finally,
inflammatory disease is defined only by the absence of evidence of stricture or penetration.
This chapter will review predictors that pertain to development of Crohn’s disease-
related complications, including surgery, reoperation, hospitalization, or severe disease
behaviour.
2.2 Conceptual model
The conceptual model used in this thesis is presented in Figure 2.1. Notably, the bi-
ologic activity is represented as an unmeasurable abstract concept. The true pathologi-
cal state will subsequently influence measurable disease characteristics, including current
stricturing or penetrating behaviour, visible signs and symptoms, extraintestinal manifes-
tations of the disease (e.g. mouth and skin ulcers) and the disease location. Thesemarkers
of disease severity are measured using clinical severity indices (in this case, the Harvey-
Bradshaw Index) and the patient and clinician will use this measure to make treatment
decisions which may involve medication or eventual surgery. CD-related complications
represent serious worsening of disease or disease-related hospitalizations. A person may
develop inflammatory bowel disease given the right combination of family history of IBD,
genetic susceptibility an environmental exposures. Implicitly I assume that a person’s so-
cioeconomic status (SES) will influence their toxic habits (i.e., smoking and drinking) and
thus may modify the severity of their pathology. Furthermore, a person’s SES will also
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impact their access to care and ability to make decisions about and afford medical treat-
ment.
Figure 2.1. Directed acyclic graph conceptual model relating predictors to CD-related
outcomes. Grey icons depict unmeasured or abstract variables. Green icons represent
measured variables in the REACT trial. The blue icon represents the outcome of CD-
related surgeries or CD-related complications. Abbreviations: socioeconomic status (SES),
inflammatory bowel disease (IBD).
Table 2.1. Vienna and Montréal classification of Crohn’s disease at diagnosis
Vienna Montréal
Age at diagnosis A1 - <40 years
A2 - ≥40 years
A1 - <17 years
A2 - 17–40 years
A3 - ≥40 years
Location of disease L1 - ileal
L2 - colonic
L3 - ileocolonic
L4 - upper GI
L1 - ileal
L2 - colonic
L3 - ileocolonic
±L4 - upper GI disease
Behaviour B1 - inflammatory
B2 - stricturing
B3 - penetrating
B1 - inflammatory
B2 - stricturing
B3 - penetrating
±p - perianal disease
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2.3 Sex
As a risk factor, the data regarding sex is equivocal at best. Most studies have not
detected any strong or statistically significant association of sex (i.e., RR = 1) [79–89], yet
others have found small yet significant increased risk for complex disease behaviour or
increased severity of disease inmales [90–94] or females [3, 95, 96]. It was recently reported
that females experience a statistically significant absolute increase in the number of TNF-
antagonist side-effects (81.3% versus 64.2%) and subsequent therapy withdrawal due to
these side-effects (35.4% versus 18.4%) [97]. Thus, sex-specific approaches to therapy may
be warranted.
2.4 Age at diagnosis
Age of diagnosis is categorized using the Vienna/Montŕeal criteria (Table 2.1). The
age of onset is approximately 10% in adolescents and children (Montréal A1), 60% in
adults 40 years old or younger (A2) and 30% in adults older than 40 years (A3) [2]. A
positive diagnosis is usually made in the patient’s twenties to early thirties, however CD
may be diagnosed older than 90 years and even as young as 6 months old. Referral cen-
tre and population-based cohorts generally find that younger age at diagnosis (A1 vs. A2
andA2 vs. A3; Table 2.1) is generally associatedwith poorer prognosis compared to older
patients at diagnosis, with hazard ratios and odds ratios typically ranging from 1.2 to 1.5.
This difference may either be with respect to greater severity of disease [79, 89, 98–100],
increased risk of surgery or time to recurrence [3, 79, 80, 98, 100–103] or a penetrating
phenotype at diagnosis [89, 104]. In contrast, others have reported no associated with age,
or the opposite finding that older age at diagnosis results in poorer prognosis compared
to younger age at diagnosis [80, 81, 83, 99, 105]. One limitation noted from all of these
studies is the insistence to categorize age rather than keep it continuous. Most studies,
but not all, align these categories to the Vienna/Montréal age groups. As a result, this
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categorization may exaggerate the true effect size and lose information from a statistical
perspective. Nevertheless, younger age at diagnosis is generally associated with poorer
prognosis.
2.5 Smoking
Smoking is the most consistent risk factor of developing CD and is associated with
more severe and refractory disease [106–109]. The pathomechanism is not yet known, yet
current smokers experience greater frequency of strictures, fistulas and a larger proportion
of perianal involvement [109–112] and extraintestinal manifestations [113].
The risks of hospitalization and first and subsequent surgery are as much as doubled
while smoking [110, 112, 114, 115] as well as post-operative complications and readmis-
sions [116]. A large UK registry found that the negative effects of smoking most notably
manifest after when diagnosedwith CD after age 40 years, suggesting a diseasemodifying
relationship between age and smoking [117]. Population-based studies consistently show
the negative effects of smoking [84, 98, 101, 105, 113, 118–121], with the notable and unex-
plained exception from Olmsted County [81, 122]. Interestingly, immunosuppressive use
was shown by Cosnes and colleagues to partially reverse the deleterious effects cigarette
smoking [107].
Smoking can also affect the response to treatment. While receiving TNF-antagonists,
smoking increases the risk of relapse [123]. The PRECISE-3 study found that smokers
were more likely to lose response to certolizumab pegol [124].
Smoking cessation is beneficial in CD. As an intervention, the disease pattern of ex-
smokers at one year were the same as never smokers [125]. Those ex-smokers also re-
quired less immunosuppressive and immunomodulatory medication [125]. These results
have also been replicated after widespread use of TNF-antagonists [126]. Thus, former
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smokers can reasonably expect to resume a similar prognosis to never smokers after one
year [117]. Interestingly, many patients with IBD are unaware of the impact of quitting
smoking [127, 128]. Smoking cessation is not only beneficial to the course of disease but
is the only known modifiable environmental risk factor, and should be included in the
design of future clinical trials.
2.6 Family history
A family history of IBD, that is having any relatives with IBD diagnoses, is a strong
predictor of also developing IBD [129, 130]. CD-patients with first-degree relatives are
enriched for risk variants of multiple IBD-associated genes compared to healthy controls
with a family history of IBD, resulting in cumulatively greater genetic risk scores [131].
Having closer consanguineous relatives with IBD is associated with increased risk of de-
veloping IBD, and being diagnosed at a slightly earlier but statistically significant younger
age, based on a 35-year study of the Danish population [132]. The incident rate ratio for
having a twin with CD is 51.4 (95% CI: 29.1, 90.7) compared to a first-degree relative (IRR
7.77, 95% CI: 7.05, 8.06) [132]. Similar results were documented in a large Spanish cohort
of 100,983 cases of IBD documented in hospitals [84], and confirming the younger age at
diagnosis. Having a close relative affected with IBD is still the greatest unmodifiable risk
factor for one to develop IBD [133].
In contrast, a family history of IBD is not generally considered a risk factor for expe-
riencing more severe disease behaviour (stricturing or penetrating activity). A few small
studies from single institutions have found risk of penetrating disease to be increased in
familial CD pairs [1, 134]. Familial CD cases have a nominally increased risk of first major
surgery by two years after diagnosis based on theDanish national cohort, and significantly
increased risk of surgery for two to 15 years after diagnosis (HR 1.60, 95% CI: 1.21, 2.11)
[135]. Familial cases of CD, identified from a large Spanish cohort, had small but signifi-
cant increases in the rates of extraintestinal manifestations, penetrating disease behaviour
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and perianal disease [84]. The risk of pouchitis, an inflammation of the lining of a pouch
that is surgically created in the treatment of IBD, in CD was tripled with a family history
of CD compared to no history of CD from a prospective study of a referral clinic [136].
Overall, a family history of CD increases the long-term risks for CD-related surgery and
complications of disease.
2.7 Site of disease involvement
The site of disease involvement has long been recognized as an important clinical char-
acteristic. Approximately one-third of patients will experience either ileal involvement,
colonic involvement or ileocolonic involvement at diagnosis [2, 137]. Up to 33% of pa-
tients will also show evidence of stricturing or penetrating complications at diagnosis [2,
137]. Disease behaviour in approximately one-third of CD patients will evolve over time
from an inflammatory disease to a stricturing and penetrating phenotype within 5 years
and 50% by 20 years (e.g., [104, 122, 138]). Progression in disease behaviour was strongly
associated with all disease locations (L1, L3, L4) other than strictly colonic disease [122].
However, the anatomic site of involvement generally remains stable over time [104, 122,
138–140].
The results from population-based cohorts are considered first. In Olmsted County,
Minnesota, ileocolonic and small bowel localization are each significantly associated with
intestinal surgery (HR 3.3 and 3.4, respectively) [141]. The IBSENpopulation-based cohort
showed that small bowel involvement (L1 or L4) increases the risk of intestinal surgery by
approximately 20% [142]. A modern Danish inception cohort further identified ileal in-
volvement (L1) to be associated with increased surgery, surgical recurrence and hospital-
ization compared to all other anatomic locations [101], providing a valuable update on the
historical inception cohort from Copenhagen County [143]. Ileal disease doubled the risk
of progression to complicated disease behaviour compared to only colonic disease (HR,
2.1) in a Hungarian cohort [144], and doubled risk of CD-related surgery (OR, 2.3) in a
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Singaporean cohort [145]. These results generally agree with an older Stockholm County,
Sweden cohort [146]. Furthermore, ileal disease was also associated with the develop-
ment of perianal disease in the Canterbury, New Zealand cohort, which in turn may lead
to more serious complications [89]. Small bowel disease leads to more rapid progression
towards complicated CD behaviour [104, 109].
While rare, jejunal disease leads to a significantly earlier first disease-related compli-
cation in Olmsted County [122] and increased risk of surgery from the IBSEN cohort [142].
The above results largely agree with large observational studies. The Inflammatory
Bowel Disease Genetics Consortium cross-sectional study showed that ileal involvement
and jejunal disease were independent risk factors for multiple surgeries and progression
to stricturing behaviour [147]. In a retrospective cohort of 2,573 patients, ileal involvement
(HR, 2.78) and the absence of rectal involvement (HR, 0.34) nearly tripled the risk of first
surgical resection [148]. Upper GI involvement was strongly associated with surgical and
non-surgical recurrence in a large European inception cohort [98]. Colonic disease was
also found to be mildly protective for resective surgery [98]. Taken together, ileal involve-
ment (especially isolated ileal disease) and jejunal involvement are strong predictors of
serious complications and need for surgery.
2.8 Perianal disease
Perianal disease encompasses a multitude of perianal manifestations, including hem-
orrhoids, anal canal lesions (anal fissures, anal ulcers and anorectal strictures), fistulas and
abscesses [149]. Perianal fistulas are especially difficult because they cause significantmor-
bidity and reduce quality of life. Perianal fistulas tend to be multiple, recur, and predict
greater disease severity, faster disease progression, and greater needmedical and surgical
intervention [79, 86, 104, 109, 146, 150]. Placebo-controlled trials also consistently show
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that the use of TNF-antagonists for the induction and maintenance of response also im-
proves healing of perianal fistulas [11, 151–156]. A meta-analysis of 12 placebo-controlled
trials also showed fistulizing disease is associated with surgical recurrence [157].
The lifetime cumulative incidence of perianal fistulas is estimated at 25-35% [87, 149].
Those with colonic involvement and especially those develop proctitis are most likely to
develop a perianal fistula [86, 93, 158]. Perianal disease is associatedwith younger age and
complicated disease behaviour [89], poorer prognosis [89, 122, 159, 160] and increased risk
of intestinal surgery [93, 158, 161, 162]. Perianal disease is also an established risk factor
for postoperative recurrence [163].
2.9 Prior surgery
Themost common operations in CD are stoma creation (colostomy or ileostomy), ileo-
colonic resection, small bowel resection with or without strictureplasty, colectomy, and
ileo-rectal anastomosis [164]. Terminal ileal disease is a common indication for ileocolec-
tomy.
While surgery is not curative of Crohn’s disease, it can temporarily induce remission
for some patients, albeit with a highly variable duration. However, it is almost inevitable
that patients will eventually have post-operative recurrence. At one year following resec-
tion, endoscopic recurrence occurs in 70-80% of patients, while 10-20% will show clini-
cal recurrence and rarely (<5%) will surgery be curative for the long-term [141, 143, 165,
166]. Surgical recurrence rates are estimated between 4-25% by one year after diagnosis
[4, 167]. However, the trend from placebo-controlled trials in the last decade have indi-
cated a decline in the annual intestinal surgery rate toward the lower end of this range.
A meta-analysis of 12 placebo-controlled trials found that prior surgery independently
also influenced endoscopic recurrence [157]. About 30-50%will require reoperation by 10
years, with a mean time to surgical recurrence of 15 years [4, 148, 167].
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Prior surgery for CD is considered a marker for for postoperative disease recurrence
and subsequent surgery [168]. For example, population-based cohorts consistently show
that prior intestinal surgerymore quickly leads to the next surgery [102, 141, 169], in agree-
ment with other reports [4, 170, 171]. The post-operative period is still one of the most
poorly understood clinical periods [170]. The authors remark that part of this poor un-
derstanding of postoperative recurrence of CD is that these studies have not applied a
universal or consistent definition of recurrence and evaluation of the primary recurrence
or re-operation and that there is inconsistent reference to the type of primary involvement
[170]. Yet, the surgical procedure itself may cause subsequent disease activity as up to
half of all Crohn’s disease patients with an anastomosis, the disease will recur at this site
[172, 173]. Overall, prior surgery is a reliable marker for disease recurrence, albeit with a
variable time frame.
2.10 Genetic factors
Genetic risk factors are an important aspect of the etiology of inflammatory bowel dis-
ease. The known variantsmostly cluster within genes related to innate immunity, mucosal
homeostasis and autophagy. The most consistent and extensively studied gene region in
association with CD is NOD2, the first risk locus identified for IBD [174]. The list of risk
loci has since expanded to over 200 [175–177], with several common to both ulcerative col-
itis (UC) and CD. Together, these identified risk loci explain only approximately 13% of
variance in disease susceptibility [177].
Genetic analysis is attractive to stratify patients by their genetic susceptibility of future
disease phenotype or complications, and even surgery. However, there are two important
limitations to consider. The first is that risk variants often have (very) low prevalence.
The second is that most of the data concerning risk loci for IBD have originated from
European cohorts of mostly Caucasian ethnicity and these results may therefore suffer
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from considerable ethnic bias. As such, the major NOD2 risk variants are not present in
individuals of East Asian descent [177].
Genetic information is of great interest, though rarely used, in risk prediction models
for CD-related complications. Nevertheless, genetic risk scores and the total number of
risk variants are useful to predict disease phenotype and site of involvement [178]. Some-
times this is due to low risk variant prevalence (e.g., [142], or only using information about
NOD2 risk variants [118, 162, 179].
2.10.1 Nucleotide-binding oligomerization domain-containing protein
2
Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) (also re-
ferred to as CARD15 or IBD1) is an intestinal bacterial peptidoglycan receptor. There
are three risk variants associated with CD (R702W, G908R and L1007fsX) [180, 181]. The
largest genetype-phenotype study of IBD patients (16,902 with CD and 12,597 with UC)
found that having a NOD2 risk variant approximately doubles the risk of developing ileal
disease compared to colonic disease, with ileocolonic disease presenting intermediate risk
[178]. The greatest risk is from the rs2066847 (3020insC/p.Leu1007fsX) mutation [178],
which happens to be the most common among Caucasians.
After accounting for disease location, NOD2 risk variants do not further increase risk
of stricturing or penetrating disease [178]. NOD2 risk variants only slightly increased risk
by 10%-31% for index surgery [178], similar to a previous meta-anaylsis [182]. However,
an different meta-analysis found that no association with surgical recurrence [183]. An
Australian cohort found that the same frame-shift mutation was associated with rapid
progression to more complicated disease and significantly earlier time to index surgery
[184].
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It’s important to consider that NOD2 status on its own can have poor predictive power
[182]. Minor allele frequencies in healthy Caucasians and Caucasians with CD are gener-
ally <5% andwith large geographic heterogeneity [178, 182, 185]. Thus, genotypingNOD2
status may only be useful for a small subset of patients.
2.11 Biomarkers
Biomarkers such as C-reactive protein (CRP), neutrophil-derived proteins, cytokines,
and anti-microbial antibodies have been investigated for their associations with disease
course and treatment outcomes.
2.11.1 Serum C-reactive protein
SerumC-reactive protein (CRP) is an acute-phase inflammation protein of systemic in-
flammation [10, 186]. Serum CRP concentrations is frequently have elevated in IBD, and
is more pronounced in CD compared to UC [19, 187–190]. This only moderately corre-
lates with the severity of inflammation and hence of disease [187]. However, a substantial
portion of individuals are genetically predisposed to not mount a serum CRP response
[10, 191–193]. Elevated serum CRP also correlates with endoscopic and severe histologic
inflammation, yet not with radiographic activity [10, 19, 194, 195]. Elevated CRP levels
also weakly correlate to relapses, possibly requiring hospitalization over the short-term
(1 to 2 years) [188, 195, 196], including in asymptomatic patients to predict future relapse
[160, 197]. These results led to the view that CRP is a sensitive marker of IBD-related
inflammation.
The association between CRP concentration and either future treatment response or
disease activity is relatively weak. Several placebo-controlled trials demonstrated that
baseline CRP concentration per se was generally not predictive of future remission status
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or substantial clinical improvement in disease-activity scores [198–203]. In contrast, an
early CRP response was shown to be a better predictor of treatment response and durable
remission [199, 204–206], in accord with findings from large prospective cohorts [18, 207–
209].
Few studies have investigated CRP as a predictor for CD-related surgery. In the IBSEN
cohort, a high CRP concentration (>53mg/L) was strongly predictive of intestinal surgery
by one year, but only for those 46 patients with terminal ileitis (L1) (OR 6.0) [190]. If CRP
remained elevated for one year with refractory CD, this also tended to suggest increased
risk of surgery for the subsequent four years [190]. Others still have found no statistically
significant association between CRP and surgery [142, 179]. Despite its limitations, serum
CRP tests are relatively inexpensive, widely available and may be readily included into
prediction models.
2.11.2 Fecal calprotectin and lactoferrin
Two fecal biomarkers, calprotectin and lactoferrin, have garnered significant interest as
surrogates of active inflammation. Calprotectin is a heterodimeric protein that binds zinc
and manganese ions and its binding activity is calcium-dependent. It is mainly produced
by neutrophils which is excreted in feces [210]. Fecal calprotectin (FC) concentrations are
significantly elevated in IBD compared to healthy controls [211–213]. Lactoferrin is an
iron-transporting globular protein, also secreted from granules of neutrophils and into
the serumbymucosal secretion. Fecal lactoferrin (FL) concentrations are elevated in active
IBD compared to inactive disease and healthy controls [214].
With respect to other biomarkers, calprotectin and lactoferrin strongly correlate (Pear-
son correlation, r > 0.6) with each other [10, 215–218], whereas fecal markers only mod-
erately correlate with CRP (Pearson correlation, 0.3 < r < 0.6) [10, 215, 218–220].
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As surrogates of disease activity
FC concentrations are moderately to strongly correlated with the severity of endo-
scopic or histologic inflammation in active CD [10, 212, 215, 216, 220–225]. Additionally,
Low FC concentrations are generally useful to discriminate between inactive and active
disease [216, 220, 222, 223]. FC correlates moderately with the HBI [212, 215] and weakly
with CDAI [212, 213, 216, 219, 225] to indicate clinically active disease.
FL concentrations are moderately to to strongly correlated with the severity of endo-
scopic or histologic inflammation in active CD, and may discriminate between inactive
and active disease [10, 216, 218, 219, 221]. However, FL correlates weakly with clinically
active disease [10, 215, 216, 218, 219].
Heterogeneity among disease location
Fecal calprotectin and lactoferrin concentrations are heterogeneous when grouped by
site of disease involvement. Active and quiescent ileal disease (Montréal L1) tend to induce
less secretion of these fecal markers compared to active colonic or ileocolonic disease [10,
216, 219, 226]. Endoscopic inflammation also correlated poorly with ileal CD [10, 216].
However, reports conflict as to whether there are significant differences among disease
location in inactive disease [10, 218–220].
Heterogeneity as predictors of post-operative recurrence
Few studies have examined the relationship between fecalmarkers and the risk of post-
operative recurrence. Fecal calprotectin and lactoferrin concentrations normalizewithin 1-
2months of intestinal surgery [215, 217]. One study showed that these fecal markers could
predict postoperative recurrence in symptomatic post-operative patients, but recurrence
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was not defined [215]. The FC concentration has been shown to prospectively predict
endoscopic recurrence following ileocolonic resection [225, 227–229].
Fecal markers, especially calprotectin, show high sensitivity in prospectively evalu-
ating surgical or endoscopic postoperative recurrence [225, 227–232]. A key limitation
in postoperative recurrence is the high variability in the choice of cut-off values for each
marker to demarcate remission from recurrence, making the clinical utility dependent on
the choice of cut-off. Ileal disease especially may be especially hard to monitor using these
fecal markers.
Diagnostic utility
Information on the comparative diagnostic performance of fecal calprotectin and lacto-
ferrin tests in IBD is relatively sparse. Nevertheless, most authors suggest that FL is supe-
rior [10, 215, 218, 233, 234]. A recent meta-analysis of the pooled diagnostic characteristics
of serum and fecal biomarkers reported that fecal biomarkers are overall more accurate
for the diagnosis of endoscopically active IBD [235]. Compared to FC, FL had nominally
lower pooled sensitivity (82% vs 88%) and nominally greater pooled specificity (79% vs
73%), while fecal markers were significantly more sensitive than CRP (sensitivity = 0.49,
95% CI: 0.34, 0.64) [235]. However, these stool biomarkers have yet to be evaluated in
clinical prediction models.
These fecal biomarker tests are yet to be perfect surrogates for the gold standard of
endoscopy for the evaluation of disease activity. However, in suspected disease, these
tests may be an added tool to expedite management while waiting for the more expensive
and invasive endoscopy [235].
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2.12 Development of clinical predictionmodels for compli-
cations and surgery related to Crohn’s disease
Subclinical transmural inflammation persists in many patients despite the use of im-
munosuppressive maintenance therapies [1]. This inflammatory process predisposes pa-
tients to complications such as strictures and fistulas [2]. Recent studies estimate the long-
term risk of surgery to be approximately 60-80% [2, 80, 141, 165], with the greatest risk in
the first few years following diagnosis. Typical symptoms experienced in CD include ab-
dominal pain and cramping, (frequent) diarrhea, blood in the stool, fever, fatigue, reduced
appetite and weight loss.
In the last two decades, the advent of biologic therapies and refinement of treatment
paradigms have revolutionized themedicalmanagement of CD. Specific advances include
the introduction of TNF-antagonists [11, 202, 203, 236–240] and integrin inhibitors [200,
201, 241–243], the use of combination therapy [76, 244–246], therapeutic drug monitoring
[247, 248] and earlier initiation of effective therapies in high-risk patients [13, 15, 16, 76,
240, 244, 245, 249, 250]. However, one of the greatest challenges to implementing these
strategies is determining which patients are most appropriate for intensive therapy. Usu-
ally this decision is based on clinical judgment and is heavily weighted by the patient’s
disease activity as assessed by symptoms. While this approach is clinically sensible it ig-
nores prognostic factors that ultimately drive the risk for disease-related complications.
Accordingly, identification of patients at highest risk of complications and disease pro-
gressionwho have the greatest chance of benefiting from early initiation of highly effective
therapy is an aspirational goal.
In this regard our approach to therapy in CD has changed dramatically. Formerly
"step care," in which drugs are used sequentially to attain symptomatic remission was the
preferred paradigm. While this approach is attractive because it avoids over-treating low
risk patients, step-care delays initiation of effective therapy in patients most at risk for
36
adverse outcomes. More recently, attention has turned to early introduction of combina-
tion immunosuppression therapy in high risk patients to promote mucosal healing and
to minimize exposure to corticosteroids [244, 245]. This "top-down" approach requires
accurate identification of high risk patients to minimize treatment-related adverse events
and costs in low-risk patients. Conversely, mis-classification of high-risk patients delays
administration of effective therapies and potentially results in increased risk of complica-
tions. Therefore, the ability to accurately risk stratify patients has garnered considerable
interest [118, 251, 252].
Retrospective analyses of single centre and population-based cohorts have identified
multiple prognostic factors in CD [1, 79, 80, 98–100, 102, 104, 118, 122, 141, 165, 252, 253]
including younger age at diagnosis; ileal disease location; perianal disease, stricturing
or penetrating phenotype (sub-clinical behaviour); current smoking; (clinically apparent)
stricturing or penetrating disease; treatment with corticosteroids at diagnosis or corticos-
teroid dependence; and extensive disease involvement.
Although several prediction models have been developed, they are encumbered by
several limitations, and none of which are in widespread use. Specifically, these models
were developed using cohorts from before the widespread use of TNF-antagonists, co-
horts from single centres, retrospective sample selection, small development samples or
predict excessively long-term risk estimates of outcome (5-10 years) [79, 100, 103, 105, 142,
179] (Table 2.2). This study is uniquely able to develop a clinical prediction model using
data from a large, controlled trial which is currently lacking in the literature. This design
is additionally advantageous to limit the possible biases from the noted limitations.
Data arising from controlled randomized trials offer a unique opportunity to develop
clinical prediction models given their scope, size, multi-centre participation and prospec-
tive nature, thus overcoming some of the aforementioned design limitations. This thesis
presents the development of prediction models using many of the predictors just pre-
sented. Specifically, the model development is based on data from the REACT study, a
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large cluster-randomized trial of two treatment algorithms for CD [76]. Multivariable lo-
gistic regression models are developed for each of the two binary outcomes: (i) a compos-
ite of CD-related surgery, disease-related complications or hospitalization, and (ii) CD-
related surgery alone. Both endpoints are defined as 24 months since patients entered the
study.
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Table 2.2. Characteristics of related clinical risk prediction models.
Beaugerie 2006 (Logistic model)
Outcome: Severe disease: more than two steroid courses or steroid dependence;
hospitalization for a flare-up or complication; cumulatively one year or more of severe
symptoms; need for immunosuppression; or intestinal surgery.
Derivation: Retrospective cohort of 1,188 adults; French centre.
Time frame: 5 years following diagnosis
Predictors: Diagnosis below 40 years; perianal lesions at diagnosis; requirement of
steroids to treat the first flare-up
Validation: Partial validation using prospective cohort of 302 adults from same centre.
Loly 2008 (Cox PH model)
Outcome: Time to severe disease: complex perianal disease; colonic resection; two or
more small-bowel resections (or a single small-bowel resection measuring >50 cm in
length) or the construction of a definite stoma.
Derivation: Retrospective cohort of 361 people, mostly adults; Belgian centre.
Time frame: 5 years following diagnosis
Predictors: Stricturing behaviour; weight loss in excess of 5 kg
Validation: None
Solberg 2014 (Logistic model)
Outcome: Severe disease: intestinal resective surgery, stricturing or penetrating disease
behaviour, or need for thiopurines.
Derivation: Prospective population-based cohort of 132 adults and children; Norway
(IBSEN)
Time frame: 5 years following diagnosis
Predictors: ASCA seropositive status (IgA or IgG), disease location (L2/L3 vs L1/L4),
age at diagnosis, corticosteroids at diagnosis
Validation: None.
Solberg 2014 (Logistic model)
Outcome: Intestinal surgery: CD-related fistula surgery or intestinal surgery.
Derivation: Population-based cohort of 190 adults and children
Time frame: 10 years following diagnosis
Predictors: ASCA seropositive status (IgA or IgG), disease location, age at diagnosis,
stricturing or penetrating behaviour, corticosteroids at diagnosis
Validation: None
Note: table continued on next page.
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Characteristics of related clinical risk prediction models continued.
Lakatos 2015 (Logistic model)
Outcome: Severe disease: having intestinal resection or progression to
stricturing/penetrating disease behaviour.
Derivation: Prospective cohort of 271 adults; Hungarian centre
Time frame: 3, 5 or 7 years following diagnosis, with >3 years disease duration
Predictors: ASCA seropositive status (IgA or IgG), disease location and need for early
azathioprine (within 3 years of diagnosis)
Validation: None
Siegel 2016 (Cox PH model)
Outcome: Time to first complication: bowel stricture, internal penetrating disease or
non-perianal surgery (bowel resection or stricturoplasty).
Derivation: Retrospective-prospective cohort of 695 adults; 2 North American centres
Time frame: 3 years following diagnosis
Predictors: Small bowel disease; left colonic disease; perianal disease; NOD2 frame-shift
mutation; seropositive status of ASCA, Cbir, ANCA; log of ASCA total antibody
concentration
Validation: Internal validation using bootstrap resampling. External validation using
multi-centre registry including 109 adults and 392 children.
Dubinksy 2013 (Logistic model)
Outcome: Resective surgery: intestinal resection only for penetrating or stricturing CD,
excluding perianal surgery or stricturoplasty
Derivation: Retrospective cohort of 1,115 adults and children; 3 American referral
centres
Time frame: 5 years following diagnosis
Predictors: NOD2 risk variant; 5 genetic variants (IL23R, IL12B, C11orf30, RXRA,
CACNA2D1)
Validation: None
Dubinksy 2013 (Cox PH model)
Outcome: Time to resective surgery: intestinal resection only for penetrating or
stricturing CD, excluding perianal surgery or stricturoplasty
Derivation: Retrospective cohort of 1,115 adults and children; 3 American referral
centres
Time frame: 5 years following diagnosis
Predictors: Multiple models were developed. The complete list of included predictors
were: NOD2 risk variant; 5 genetic variants (IL12B, SLC22A4, 21q21, ZNRF1); sex, age at
diagnosis <16 years, stricturing or penetrating behaviour, ANCA serology, disease
duration, small bowel disease location.
Validation: Internal validation only using cross-validation.
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Chapter 3
Methods
3.1 Data source
The dataset includes all participants from theRandomizedEvaluation of anAlgorithm
for Crohn’s Disease (REACT) trial, as previously reported [76] (NCT01030809). Briefly,
REACT was a large cluster-randomized, controlled trial of two distinct algorithms for the
management of CD. Forty Canadian and Belgian community-based gastroenterology clin-
ics were randomized, in a 1:1 ratio, to either early combined immunosuppression (ECI) or
step care. In each cluster, consecutive adult (18 years or older) patients with CD were en-
rolled from urban community clinics, regardless of disease activity or concurrent therapy,
and followed up to 24 months. Two separate models were developed to predict the risk
over 24 months of having (i) CD-related surgery, and (ii) a composite outcome consisting
of the first occurrence of CD-related surgery, complications or hospitalization (the latter
is henceforth referred to as a disease-related complication). The flow chart for patient
recruitment throughout the trial is presented in Figure 3.1.
The reporting of this study conforms to the Transparent Reporting of a multivariable pre-
diction model for Individual Prognosis or Diagnosis (TRIPOD) statement [25].
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Figure 3.1. Trial profile flow diagram. Adapted from Khanna et al. [76].
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3.2 Clinical outcomes and definitions
Two binary outcomeswere definedwithin two years of follow up. The first was the oc-
currence of CD-related surgery. The second was a CD-related complication. Surgery was
considered separately since it is a readily measured event that is important to patients.
All of the events in the REACT studies were evaluated by an adjudication committee who
were blinded to treatment assignment. Disease-related surgeries included resective bowel
surgery (for example, ileal resection, ileocecal resection, proctocolectomy, colectomy, en-
terectomy, ostomy formation and repair), fistula repair (incision and drainage of abscess,
seton placement, fistulotomy, fistulectomy), (re)anastomosis and strictureplasty. Disease-
related complications were defined as serious worsening of disease (development of pen-
etrating or stricturing disease, serious rectal bleeding, abdominal pain, increased bowel
frequency), serious extra-intestinal manifestations, severe perianal disease, fistula or ab-
scess [76].
3.3 Selection of predictors
Predictorswere selected from the demographic and disease-related variables collected
at baseline using standard clinical definitions. These are referred to here as baseline pre-
dictors. A search of the literature concerning potentialmarkers and risk factors for Crohn’s
disease outcomes identified potential items of interest thatwere augmented through items
identified by clinical judgment. These variables were age at enrollment, age at diagnosis,
gender, smoking status, disease location, perianal disease, prior surgical resection for CD,
use of eachmedication at baseline including 5-aminosalicylates, corticosteroids, immuno-
suppressives andTNF-antagonists, abdominal pain, abdominalmass, extra-intestinalman-
ifestations, strictures, fistula status and stool frequency. No laboratory parameters, biomark-
ers or cross-sectional imaging items were included. Treatment allocation was intention-
ally excluded in our prediction models for two reasons. First, the primary interest was to
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develop predictionmodels using only baseline predictive factors that are available in prac-
tice. Second, the effect of treatment was found to be relatively small as compared with the
factors in our prediction models (OR, 1.4-1.5). This is consistent with prediction literature
in other areas such as cardiovascular disease [254].
Age at diagnosis was considered first as a predictor since it forms part of the Vi-
enna/Montréal classification system and it is commonly understood that age at diagno-
sis is associated with disease severity and associated complications, as discussed earlier.
However, age at diagnosis did not have a statistically significant association with either
outcome (OR = 1.00). Since age at baseline was highly correlated with age at diagnosis
(Pearson’s r = 0.74), this was substituted in place of age at diagnosis, and was found to
have a more precise and stronger effect than age at diagnosis. Medication use at baseline
is important to consider since these modulate disease activity.
A commonly used clinical index of disease severity is the Harvey-Bradshaw Index
(HBI) [255]. The HBI score (Table 3.1) is a simple tally of symptom-related items (e.g., ex-
traintestinal manifestations, complications of disease, general well-being) and frequency
of liquid stools. By dividing the HBI into the components and stool frequency, more vari-
ation of the disease outcomes could be explained than when just using the HBI score. For
example, a patient may be considered to be out of remission (HBI > 4) because they have
frequent diarrhea, or because of much more serious symptoms (e.g., severe abdominal
pain and a fistula). However, the clinical severity of the latter situation is much more se-
vere than the former. Furthermore, many patients with inactive Crohn’s disease still have
frequent stools, which may be managed with anti-diarrheals or dietary modifications, yet
the stool frequency can contribute themost out of any other item in theHBI score. Patients
with objectively mild disease tend to have 2-4 stools per day, whereas patients with more
active andmore severe disease will also have substantiallymore frequent stools (often >8).
Therefore, the HBI score was divided into these two components and an interaction be-
tween them was introduced in the modeling process to account for non-additive effects
(on the log odds scale).
44
Table 3.1. Harvey-Bradshaw index
Item Item Value
General well-being Very well (+0)
Slighty below average (+1)
Poor (+2)
Very poor (+3)
Terrible (+4)
Abdominal pain (yesterday) None (+0)
Mild (+1)
Moderate (+2)
Severe (+3)
Number of liquid or soft stools yesterday Add
Abdominal mass None (+0)
Dubious (+1)
Definite (+2)
Definite and tender (+3)
Complications (check all that apply, +1 point each) Arthralgia
Uveitis
Erythyma nodosum
Aphthous ulcers
Pyoderma gangrenosum
Anal fissure
New fistula
Abscess
Total HBI score = sum of points for each item.
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3.4 Missing data and loss to follow up
There were 4.2% (n=84) of participants that had at least one missing variable at base-
line. In the original trial, there were 323 participants that (323/1982, 16.3%) were lost to
follow up. These individuals were kept in the the study since they were followed for at
least some duration and were considered to have not had the outcome during their follow
up time. Because of a large sample size, only participants with complete baseline data
were used for model development.
3.5 Model development
Exploratory univariate data analysis was initially conducted to assess adequate event
frequency between each outcome and the candidate predictors. Univariable associations
between candidate predictors and the outcomes were assessed by simple logistic regres-
sion. Each model was then constructed using multivariable logistic regression providing
log-odds ratios and standard errors.
Candidate predictors were selected arbitrarily by a manual review of the literature
augmented by expert clinical opinion. Unnecessary variables were removed by evaluation
of performance in bootstrap replicates. Since the focus was to predict individual risk, the
standard logistic regression approach could still be applied even though the data arose
from a cluster-randomized trial, as the degree of clustering mainly inflates te estimated
standard errors of the coefficients, and an intra-class correlation coefficient less than 0.05
does not much affect prediction performance [256, 257].
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3.6 Predictive performance and model validation
Model performance was characterized by the discrimination ability and calibration.
Discrimination refers to the capacity of a prediction model to distinguish between pa-
tients with the outcome and patients without the outcome. In the present context, dis-
crimination is measured using the c-statistic, which is identical to the area under the re-
ceive operating characteristic curve [45]. A value of 0.50 for the c-statistic represents the
prognostic ability of a coin flip, suggesting a model without discrimination ability. There
are no accepted guidelines on assigning qualitative labels to the degree magnitude of dis-
crimination. We arbitrarily considered discrimination values below 60% are unacceptable,
60-70% are acceptable and greater than 70% are considered good to excellent. Model dis-
crimination may also be visualized by a discrimination plot, wherein the distributions of
predicted probabilities are compared for those with and without the outcome. The slope
of the discrimination plot is then the mean difference in predicted values. The greater the
separation between groups, or slope, implies greater discrimination.
Calibration refers to the agreement between predicted and observed risks [21]. This
can be assessed by plotting the predicted risks and the actual percentages of patients who
have the outcome. The Brier score measures overall prediction errors. It is the original
(apparent) accuracy, or average prediction error, and is calculated as the mean square of
the difference between the observed outcome and predicted outcome probability. Calibra-
tion curves are useful to examine the model fit and validation process. Linear scores from
amodel are used to predict the observed outcomes. The curves showwhether predictions
are systematically too large or too small (called calibration-in-the-large) [45]. Since model
development tends to over-fit the data, commonly referred to as optimism, this would
result in predictions that are too extreme. The prediction model is said to have poor cali-
bration when this type of extreme prediction occurs. Therefore, it is preferable to reduce
optimism using internal validation or external validation [30].
Internal validation of the final model was performed using a bootstrap procedure that
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was specifically designed for prediction models [258]. This procedure proceeds with the
following steps. First, draw a sample (with replacement) of the same size as the original
data set. Second, build a prediction model using the bootstrap sample and obtain the per-
formance indices (termed bootstrap performance indices). Apply this model to the origi-
nal data and obtain model performance indices (termed test performance indices). Third,
obtain estimates of optimism by subtracting test performance indices from bootstrap per-
formance indices. Next, repeat steps one to three several times and obtain the average of
the optimism. This thesis project used 500 repetitions. Lastly, the optimism-corrected per-
formance indices are computed by subtracting the average amount of optimism from the
performance indices obtained using the original data. The optimism-corrected calibra-
tion slope can then be used to shrink regression coefficients in the prediction model [45].
Shrinking coefficients is analogous to regression toward the mean which provides more
accurate risks for new individuals. Index performance characteristics were calculated for
the initial and validated models following correction for optimism.
3.7 Score charts, nomograms and clinical utility
Score charts were derived from the regressionmodel equations and simplified for ease
of use [259]. The integer sum from all of the predictors in a model can then be converted
to a risk estimate using the conversion chart at the bottom of the score chart. Each model
is accompanied by a nomogram for risk estimation.
Clinical utility was evaluated using the net benefit index and is graphically repre-
sented using a decision curve [52, 53]. At a specified risk threshold, the net benefit (NB)
summarizes how many additional true-positive classifications can be made when using a
model compared to not, without sacrifice to the false-positive rate [52]. The NB considers
the harm of being treated unnecessarily (i.e., a false-positive compared to a true-negative)
to the benefit of avoiding treatment where none was necessary (i.e., a true-negative com-
pared to a false-negative). A decision curve can be plotted from all possible NB values.
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3.8 Sample size
Formal sample size calculationwas not performed due to the lack of a formula. Never-
theless, there were 1982 participants in REACT trial, among them 504 had disease-related
complications and 130 had surgeries over two years of follow up. According to the guide-
line of 10 events per variable [36], this dataset is large enough to construct predictionmod-
els with at most ten degrees of freedom.
3.9 General statistical methods
Statistical analysiswas performedusing Stata (version 14.1/IC; StataCorp, College Sta-
tion, TX), R (version 3.3.1; Linux; R Core Team) and RStudio (version 0.99; RStudio Team)
software packages. Summary statistics are presented as mean ± standard deviation (SD),
median or frequencies and proportions as appropriate.
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Chapter 4
Results
4.1 Patient characteristics and model specifications
The REACT trial enrolled 1,982 patients. From this, 84 patients had some degree of
missing baseline predictor information and were excluded from the present analysis. Of
the 1,898 (1,982 - 84) patients included, 1,097 (58%) were female. Other baseline character-
istics are outlined in Table 4.1. Median disease duration was 148.8 months, and patients
had, for themost part, predominantly lowdisease activity (meanHBI score = 4.1). Overall,
6.9% (n=130) underwent CD-related surgery, whereas 26.6% (n=504) of participants expe-
rienced a CD-related complication. Univariate associations for each outcome are shown
in Table 4.3.
A table presenting pairwise correlations between potential predictors and each out-
come is presented in Table 4.2. Most correlations among predictors are small (Pearson’s
r < 0.15). Note that age at baseline and age at diagnosis were very strongly positively
correlated (r=0.74). As expected, total HBI score is also strongly correlated with the stool
frequency component (r=0.88) and the remaining symptom-based components (r=0.71).
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Table 4.1. Overall patient characteristics in REACT.
Patient Characteristics Overall
N=1,898
Surgery
group
N=130
6.9%
No surgery
group
N=1,768
93.1%
Complication
group
N=504
26.6%
No compli-
cation group
N=1,394
73.5%
Demographics
Age, years (mean ± SD) 44.0 ± 14.6 42.7 ± 14.0 44.1 ± 14.6 42.1 ± 14.6 44.7 ± 14.5
Gender, female 1,097
(57.8%)
68 (52.3%) 1,029 (58.2%) 311 (61.7%) 786 (56.4%)
Smoking history at baseline
Non-smoker 939 (49.5%) 58 (44.6%) 881 (49.9%) 241 (47.9%) 698 (50.1%)
Ex-smoker 550 (29.0%) 36 (27.7%) 514 (29.1%) 405 (29.1%) 145 (28.8%)
Current smoker 407 (21.5%) 36 (27.7%) 371 (21.0%) 290 (20.8%) 23.3 (117%)
Disease characteristics
Duration, months [mean (me-
dian)]
148.8 (119) 144.8 (111.1) 149.1 (119.2) 147.0 (114.0) 149.5 120.9
HBI score at baseline [median;
mean ± SD]
3; 4.1 ± 1.1 5; 6.0 ± 3.5 3; 4.0 ± 1.1 4; 5.0 ± 4.9 3; 3.8 ± 3.8
Steroid-free remission (HBI 4)
at baseline
1,065
(56.1%)
51 (39.2%) 1,014 (57.4%) 236 (46.8%) 829 (59.5%)
Involved intestinal areas
Colon 417 (22.0%) 17 (13.1%) 400 (22.6%) 92 (18.3%) 325 (23.3%)
Small bowel 654 (34.5%) 52 (40.0%) 602 (34.1%) 169 (33.5%) 485 (34.8%)
Colon and small bowel 827 (43.6%) 61 (46.9%) 766 (43.3%) 243 (48.2%) 584 (41.9%)
Extra-intestinal manifestations
at baseline
594 (31.3%) 55 (42.3%) 539 (30.5%) 185 (36.7%) 409 (29.3%)
Prior history for disease-related
surgery
864 (45.5%) 56 (43.1%) 808 (45.7%) 244 (48.4%) 620 (44.5%)
Medications at baseline
Aminosalicylates 539 (28.4%) 22 (16.9%) 517 (29.2%) 116 (23.0%) 423 (30.3%)
Corticosteroids 348 (18.3%) 31 (23.9%) 317 (17.9%) 113 (22.4%) 235 (16.9%)
Antimetabolites 826 (43.5%) 48 (36.9%) 778 (44.0%) 204 (40.5%) 622 (44.6%)
TNF-antagonists 622 (32.8%) 53 (40.8%) 569 (32.2%) 201 (39.9%) 421 (30.2%)
Note: Values are presented as [n (%)], unless otherwise specified. Figures vary slightly from those in Khanna et al.
(2015) due to 84 patients with at least one missing baseline variable.
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Table 4.2. Pair-wise Pearson correlation matrix among considered predictors for Crohn’s
disease-related complications or surgery.
A B C D E F G H I J K L M N
A 1
B 0.74* 1
C -0.02 -0.01 1
D -0.12* -0.21* 0.02 1
E 0.13* -0.18* 0.03 0.23* 1
F 0.01 -0.08* -0.1* 0.08* 0.14* 1
G 0.04 -0.08* -0.07* 0.08* 0.21* 0.88* 1
H -0.03 -0.05* -0.13* 0.07* 0.02 0.71* 0.39* 1
I -0.02 -0.03 -0.01 0.05* 0.01 0.21* 0.06* 0.36* 1
J -0.02 0.02 -0.01 -0.03 -0.07* 0.21* 0.16* 0.24* 0.04 1
K -0.05* -0.03 0.05* 0.01 0.01 0 -0.03 0.05* 0 -0.01 1
L -0.15* -0.15* 0.02 0.09* 0.06* 0.04 0.04 0.03 -0.01 -0.09* -0.08* 1
M -0.03 -0.02 0.03 0.04 -0.01 0.12* 0.06* 0.18* 0.25* 0.04 -0.04 0.05* 1
N -0.08* -0.08* -0.05* 0.06* 0.03 0.13* 0.09* 0.14* 0.14* 0.06* -0.04 0.09* 0.45* 1
Note: * denotes significance at 0.05 level.
A = Age at baseline
B = Age at diagnosis
C = Sex
D = Disease location
E = Number of previous surgeries
F = Baseline total HBI score
G = Baseline stool frequency
H = Baseline HBI score (except stool component)
I = Fistula, abscess or abdominal mass
J = Baseline steroid use
K = Baseline antimetabolite use
L = Baseline TNF-antagonist use
M = CD-related Surgery outcome
N = CD-related complication outcome
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Table 4.3. Univariate associations for Crohn’s disease-related complications or surgery.
Surgery model Complication model*
Baseline variable OR (95% CI) P-value OR (95% CI) P-value
Current age (year) 0.99 (0.98, 1.00) 0.27 0.99 (0.98, 1.00) <0.0001
Gender (male vs. female) 1.27 (0.89, 1.81) 0.19 0.80 (0.65, 0.99) 0.04
HBI score (except stool freq.) 1.36 (1.25, 1.48) <0.0001 1.18 (1.12, 1.24) <0.0001
Stool frequency (total from
yesterday)
1.08 (1.15, 1.02) <0.01 1.07 (1.03, 1.11) 0.0001
Location of disease
Colon only (ref.) 1 0.03 1 0.02
Small bowel and colon 1.87 (1.08, 3.25) 1.47 (1.12, 1.94)
Small bowel only 2.03 (1.16, 3.57) 1.23 (0.92, 1.65)
Presence of new fistula, abscess
or definite abdominal mass (yes
vs no)
10.29 (6.23, 16.99) <0.0001 3.94 (2.48, 6.26) <0.0001
Antimetabolite use (yes vs no) 0.75 (0.52, 1.08) 0.11 0.84 (0.69, 1.04) 0.1
5-Aminosalicylate use (yes vs no) 0.49 (0.31, 0.79) <0.01 0.69 (0.54, 0.87) <0.01
Corticosteroid use (yes vs no) 1.43 (0.94, 2.18) 0.1 1.43 (1.11, 1.84) <0.01
TNF-antagonist use (yes vs no) 1.45 (1.01, 2.09) 0.05 1.53 (1.24, 1.89) <0.0001
Smoking status
Non-smoker (ref.) 1 1
Ex-smoker 1.06 (0.69, 1.64) 0.28 1.04 (0.82, 1.32) 0.77
Current smoker 1.47 (0.96, 2.27) 0.08 1.17 (0.90, 1.52) 0.24
Note: * CD-related complication is the first occurrence of a CD-related surgery, hospitalization or complica-
tion.
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4.2 Model performance
Separate logistic regression models were estimated for CD-related surgery (Table 4.4)
and CD-related complication (Table 4.5) by 24 months. The original and validated log-
odds coefficients are presented for both models. The baseline predictors included in the
surgery model were age, gender, disease location, HBI score, stool frequency, immuno-
suppressive use, 5-aminosalicylate use and the presence of a fistula, abscess or abdom-
inal mass. The baseline predictors for the disease-related outcome model also uniquely
included the use of corticosteroids and TNF-antagonists, in addition to all the variables
identified for surgery.
Table 4.4. Risk prediction model for Crohn’s disease-related surgery.
Baseline predictor Original β Optimism corrected β† SE(β) P-value
Intercept −3.607 −3.511 0.327 < 0.0001
Age subtract 45 years −0.0027 −0.0025 0.007 0.72
Male vs female 0.3946 0.3634 0.194 0.06
HBI score (except stool frequency) 0.2425 0.2234 0.065 < 0.001
Stool frequency* 0.0741 0.0683 0.06 0.25
Location of disease
Colon only (ref.) 0 0 – –
Small bowel and colon 0.3614 0.3328 0.293 0.26
Small bowel only 0.5167 0.4759 0.297 0.11
Antimetabolite use −0.4519 −0.4162 0.2 0.04
5-aminosalicylate use −0.6015 −0.554 0.253 0.03
Presence of new fistula, abscess
or definite abdominal mass
1.7019 1.5674 0.306 < 0.0001
Interaction
HBI score × Stool frequency −0.0182 −0.0167 0.014 0.22
Notes: SE, standard error. † theβ coefficients are presented after shrinkage (shrinkage factor = 0.92).
* Stool frequency has a maximum value of 12.
4.3 Model validation and calibration
The original andvalidatedperformance statisticswere computed for eachmodel (Table
4.6). The validated discrimination ability for the CD-related surgery model was good,
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with a c-statistic of 0.70, whereas the discrimination ability of disease-related complica-
tion model was acceptable at 0.62 (Table 4.6).
Table 4.5. Risk prediction model for a Crohn’s disease-related complication.
Baseline predictor Original β Optimism corrected β† SE(β) P-value
Intercept −1.6134 −1.552 0.162 < 0.0001
Age subtract 45 years −0.0102 −0.0092 0.004 0.02
Male vs female −0.1848 −0.1669 0.11 0.13
HBI score (except stool frequency) 0.1139 0.1028 0.042 0.01
Stool frequency* 0.0752 0.0679 0.034 0.04
Location of disease
Colon only (ref.) 0 0 – –
Small bowel and colon 0.2525 0.228 0.145 0.12
Small bowel only 0.1739 0.157 0.153 0.31
Steroid use 0.2465 0.2226 0.138 0.11
Antimetabolite use −0.1598 −0.1443 0.11 0.19
TNF-antagonist use 0.3887 0.351 0.114 < 0.01
Presence of new fistula, abscess
or definite abdominal mass
1.084 0.9789 0.261 < 0.001
Interaction
HBI score × Stool frequency −0.0136 −0.0123 0.009 0.18
Notes: SE, standard error. † theβ coefficients are presented after shrinkage (shrinkage factor = 0.90).
* Stool frequency has a maximum value of 12.
Both models show low degrees of optimism (shrinkage coefficients were 0.92 for the
CD-related surgery model and 0.90 for the CD-related complication model) (Table 4.6).
Each model had overall moderate prediction error as measured by the Brier score. Both
models have good calibration (Figures 4.1 and 4.2) and goodness-of-fit statistics. Themod-
els for CD-related surgery (H-L χ2(8) = 3.65;P = 0.89) and CD-related complication (H-L
χ2(8) = 10.30;P = 0.24) following optimism correction. The average difference in pre-
dicted risk was 8% greater for having CD-related surgery compared to not having surgery,
and 5% greater for having the CD-related complications compared to not having the com-
plications (Figures 4.3 and 4.4). While surgery was less prevalent than the disease-related
complications, the surgical predictive model was more accurate. The calibration curves
trend upward since a few individuals in the high predicted risk of surgery group had
experienced the outcome.
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Figure 4.1. Original (A) and bootstrap validated calibration curves (B) for the CD-related
surgery model. The proportion of patients that experienced a CD-related surgery was
6.9%. The ideal line (gray line) represents predicted and observed risks perfectly match.
A flexible calibration curve is drawn for observed calibration (black line). Risk predictions
were grouped into deciles and plotted (triangles) with vertical lines representing 95% con-
fidence intervals. The bottom of each plot shows the distribution events and non-events
over the range of predicted risks.
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Figure 4.2. Original (A) and bootstrap validated calibration curves (B) for the CD-related
complication model. The proportion of patients that experienced a CD-related complica-
tion was 26.6%. The ideal line (gray line) represents predicted and observed risks perfectly
match. A flexible calibration curve is drawn for observed calibration (black line). Risk pre-
dictions were grouped into deciles and plotted (triangles) with vertical lines representing
95% confidence intervals. The bottom of each plot shows the distribution events and non-
events over the range of predicted risks.
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Figure 4.3. Original (A) and bootstrap validateddiscriminationplots (B) for theCD-related
surgery model. The discrimination slope is the difference in average predicted risk be-
tween those who did or did not experience the event.
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Figure 4.4. Original (A) and bootstrap validateddiscriminationplots (B) for theCD-related
complication model. The discrimination slope is the difference in average predicted risk
between those who did or did not experience the event.
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Table 4.6. Summary of original and bootstrap optimism-corrected performance measures
(500 bootstrap replicates).
CD-related surgery model
Statistic Index Perfor-
mance
Optimism Corrected
Statistic
Range Ideal
Nagelkerke’s R2 0.133 0.0252 0.107 [0, 1] 1
Calibration Intercept 0 0.18 -0.18 (-Inf, +Inf) 0
Calibration Slope 1 0.079 0.921 (-Inf, +Inf) 1
C-statistic 0.719 0.0243 0.695 [0, 1] 1
Dxy 0.438 0.0486 0.39 [0.5, 1] 1
Brier score 0.058 -0.0013 0.059 [0, 0.5] 0
Brier (max) 0.064
Brier (scaled) 0.088 – 0.072 [0,1] 1
CD-related complication model
Statistic Index Perfor-
mance
Optimism Corrected
Statistic
Range Ideal
Nagelkerke’s R2 0.0683 0.0145 0.0538 [0, 1] 1
Calibration Intercept 0 0.0941 -0.0941 (-Inf, +Inf) 0
Calibration Slope 1 0.097 0.903 (-Inf, +Inf) 1
C-statistic 0.636 0.0139 0.622 [0, 1] 1
Dxy 0.271 0.0278 0.243 [0.5, 1] 1
Brier score 0.185 -0.0024 0.0188 [0, 0.5] 0
Brier (max) 0.195
Brier (scaled) 0.049 – 0.036 [0,1] 1
Notes: Optimism is estimated as the difference of the training and test estimates.
Dxy = (c + 1)/2. Nagelkerke’s R2 and Dxy are provided as additional measures of model fit, see e.g., Harrell (2015).
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Figure 4.5. Nomogram for the computation of CD-related surgery risk.
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Figure 4.6. Nomogram for the computation of CD-related complication risk.
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4.4 Computing a risk estimate, the score chart and thenomo-
gram
For an individual patient, the predicted risk estimate is calculated as demonstrated as
follows. The procedure for computing a risk estimate for a patient involves multiplying
each β coefficient with the value of the associated variable. These are summed together
with the intercept to produce a linear predictor, lp, such that lp = Intercept + [X1 × β1 +
X2 × β2 + ... +Xn × βn]. The lp is converted to a risk estimate using the inverse log-odds
formula, risk (%) = 100%× 1
1+exp (−lp) . The presence of a condition takes a value of 1, while
its absence takes a value of 0.
As an example, suppose a 50 year old male patient presents to the clinic with disease
confined to the small bowel. His total HBI score is 3 with a stool frequency of 2 per day,
he is currently taking 5-aminosalicylates and does not have a fistula, stricture or definite
abdominal mass. The clinician would now like to predict their risk of surgery within the
next two years.
Start by plugging these values into the equation for the linear predictor.
lp = −3.511 + (−0.0025)× (50 − 45; age, years)+
(0.3634)× (1;male) + (0.2234)× (1point; HBI subtract stools/day)+
(0.0683)× (2 stools/day) + (0.4759)× (1; small bowel only)+
(−0.4162)× (0; antimetabolite use) + (−0.5540)× (1; 5−ASA use)+
(1.5674)× (0; fistula, abscess, or abdominal mass)+
(−0.0167)× (1 point; HBI subtract stools/day)× (2 stools/day)+
= −2.912
Now convert the linear predictor into percent risk.
Risk = 100%× 11+exp(−lp) = 5.2% (expected risk is 5.2%)
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Alternatively, a risk score may be computed using score charts (Tables 4.7 and 4.8) and nomo-
grams (Figures 4.5 and 4.6) which may then be converted into a risk estimate.
For prediction of CD-related surgery, the score ranges from 0 to approximately 203 (Tables
4.7). A score of 130 predicts a 25% chance of requiring surgery within 24 months follow up, a score
of 171 predicts a 50% chance of surgery within 24 months of follow up and a score of 203 predicts
greater than 70% chance of surgery within 24 months of follow up.
For prediction CD-related complications, the score ranges from 0 to approximately 266 (Tables
4.8). A score of 88, 177 or 266 respectively predict a 25%, 50% or 75% chance of experiencing a
disease-related complication within 24 months of follow up.
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Figure 4.7. Decision curves of clinical net benefit for the models predicting Crohn’s
disease-related (A) surgery and (B) complications. The preferred model is the model with
the highest net benefit at a given threshold. The choice of prevalence is the value at which
net benefit ismaximized, while the additional risk thresholdswere chosen to be arbitrarily
larger for the purposes of illustration.
4.5 Decision curve analysis and clinical net benefit
Positive clinical net benefit indicates potential improvement to the clinician’s ability to risk
stratify patients. Bothmodels showpositive net benefit over awide range of risk thresholds (Figure
4.7; Table 4.9). Additionally, the decision curves are superior to the default “treat all” or “treat
none” strategies implying improved prediction compared to not using suchmodels. Multiple clas-
sification statistics were computed for range of risk thresholds for illustration, including: true and
false positives and negatives, sensitivity, specificity, true and false positive classification rate, net
benefit and interventions avoided (Table 4.9).
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Table 4.7. Score chart for risk of CD-related surgery.
Choose HBI score (without stool frequency) when stool frequency is
HBI 0 times/day 2 times/day 4 times/day 6 times/day
0 0 5 10 15
1 8 12 16 20
2 17 19 22 24
3 25 26 28 29
4 33 33 34 34
5 42 41 39 38
6 50 48 45 43
7 58 55 51 47
8 67 62 57 52
9 75 69 63 57
10 83 76 69 61
11 92 83 74 66
12 100 90 80 70
Patient’s Age (years) Gender
20 to 29 6 Male 14
30 to 39 5 Female 0
40 to 49 4
50 to 59 3 Disease location
60 to 69 2 Colon 0
70 to 79 1 Colon and small bowel 12
80 years or older 0 Small bowel 18
Baseline antimetabolite use Baseline 5-aminosalicylate use
No 16 No 21
Yes 0 Yes 28
New fistula, abscess or definite abdominal mass
No 21
Yes 0
Total the points, then convert them to predicted risk using the below scale.
Total Points Predicted Risk Points Predicted Risk
0 <1% 130 25%
26 2% 139 30%
41 3% 148 35%
52 4% 156 40%
61 5% 163 45%
68 6% 171 50%
74 7% 178 55%
80 8% 186 60%
89 10% 194 65%
106 15% 203 >70%
119 20%
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Table 4.8. Score chart for risk of a CD-related complication.
Choose HBI score (without stool frequency) when stool frequency is
HBI 0 times/day 2 times/day 4 times/day 6 times/day
0 0 11 22 33
1 8 17 26 35
2 17 24 31 38
3 25 30 35 40
4 33 36 39 42
5 42 43 44 45
6 50 49 48 47
7 58 55 52 49
8 67 62 57 52
9 75 68 61 54
10 83 74 65 56
11 92 81 70 59
12 100 87 74 61
Patient’s Age (years) Gender
20 to 29 45 Male 0
30 to 39 37 Female 14
40 to 49 30
50 to 59 22 Disease location
60 to 69 15 Colon 0
70 to 79 7 Colon and small bowel 18
80 years or older 0 Small bowel 13
Baseline antimetabolite use Baseline TNF-antagonist use
No 12 No 0
Yes 0 Yes 28
Baseline steroid use
New fistula, abscess or definite
abdominal mass
No 0 No 0
Yes 18 Yes 79
Total the points, then convert them to predicted risk using the below scale.
Total Points Predicted Risk Total Points Predicted Risk
0 <10% 161 45%
37 15% 177 50%
65 20% 193 55%
88 25% 210 60%
109 30% 227 65%
127 35% 247 70%
144 40% >266 >75%
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Table 4.9. Original and optimism-corrected classification table of the CD-related models
for selected risk thresholds.
Surgical Model, Original
Threshold NB Interventions
avoided*
TP FP FN TN TPR FPR PPV NPV
6.8% (Prev.) 0.02 27.1 73 506 57 1262 56.2% 28.6% 12.6% 95.7%
7.0% 0.02 28.3 73 472 57 1296 56.2% 26.7% 13.4% 95.8%
8.0% 0.017 33.4 61 354 69 1414 46.9% 20.0% 14.7% 95.3%
9.0% 0.014 37.9 49 251 81 1517 37.7% 14.2% 16.3% 94.9%
10.0% 0.013 42.9 45 187 85 1581 34.6% 10.6% 19.4% 94.9%
Surgery Model, Validated
Threshold NB Interventions
avoided*
TP FP FN TN TPR FPR PPV NPV
6.8% (Prev.) 0.02 27.2 78 524 52 1244 60.0% 29.6% 13.0% 96.0%
7.0% 0.02 28.4 73 489 57 1279 56.2% 27.7% 13.0% 95.7%
8.0% 0.017 33.4 63 359 67 1409 48.5% 20.3% 14.9% 95.5%
9.0% 0.014 37.9 49 248 81 1520 37.7% 14.0% 16.5% 94.9%
10.0% 0.013 43.1 45 181 85 1587 34.6% 10.2% 19.9% 94.9%
Complication Model, Original
Threshold NB Interventions
avoided*
TP FP FN TN TPR FPR PPV NPV
26.6% (Prev.) 0.056 15.8 295 507 209 887 58.5% 36.4% 36.8% 80.9%
27.0% 0.054 16.3 281 482 223 912 55.8% 34.6% 36.8% 80.4%
28.0% 0.046 17.1 254 436 250 958 50.4% 31.3% 36.8% 79.3%
29.0% 0.041 18.4 238 381 266 1013 47.2% 27.3% 38.4% 79.2%
30.0% 0.036 19.8 210 337 294 1057 41.7% 24.2% 38.4% 78.2%
31.0% 0.029 20.8 187 298 317 1096 37.1% 21.4% 38.6% 77.6%
32.0% 0.024 22.1 163 253 341 1141 32.3% 18.1% 39.2% 77.0%
Complication Model, Validated
Threshold NB Interventions
avoided*
TP FP FN TN TPR FPR PPV NPV
26.6% (Prev.) 0.056 15.6 296 512 208 882 58.7% 36.7% 36.6% 80.9%
27.0% 0.054 16.2 282 485 222 909 56.0% 34.8% 36.8% 80.4%
28.0% 0.046 17.1 252 432 252 962 50.0% 31.0% 36.8% 79.2%
29.0% 0.04 18.3 234 372 270 1022 46.4% 26.7% 38.6% 79.1%
30.0% 0.035 19.5 204 324 300 1070 40.5% 23.2% 38.6% 78.1%
31.0% 0.028 20.6 175 278 329 1116 34.7% 19.9% 38.6% 77.2%
32.0% 0.023 21.9 154 236 350 1158 30.6% 16.9% 39.5% 76.8%
Notes: NB, net benefit, TP, true positives; TN, true negatives; FP, false positives; FN, false negatives; TPR, true
positive rate (sensitivity); FPR, false positive rate (1 - specificity).
* Interventions avoided per 100 people.
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Chapter 5
Discussion and conclusions
5.1 Discussion of results
Two clinicalmodelswere developed and internally developed for predicting risk of ex-
periencing CD-related complications and CD-related surgery within 24 months of follow
up, using data from one of the largest clinical trials of CD patients to date [76]. Although
both models demonstrated high specificity and negative predictive values, the surgery
model had greater predictive ability, likely because surgery is an easily defined and more
objective clinical outcome, in distinction to disease-related complications. In addition, the
development of a score chart using basic clinical variables which are readily calculable fa-
cilitates implementation of this score in the out-patient clinic setting, allowing enhanced
decision making between patients and their physicians.
The baseline predictors identified in the CD-related prediction models, especially dis-
ease activity, presence of fistula, abscess or abdominal mass, and medication use, were
all prospectively defined and measured. This is a distinct advantage to retrospective co-
hort studies in which a greater potential exists for bias during the data collection process.
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Use of this model may help to discriminate those at higher risk of disease-related com-
plications and surgery and thus may benefit most from more intensive treatment and or
combination therapy, or closer monitoring for development of disease related symptoms
that require planned surgery (e.g. obstructive symptoms in the setting of fibrostenotic
disease).
Prediction of CD-related complications is limited by the use of non-standardized or
broadly inclusive outcome definitions (Table 2.2). This may explain the lower perfor-
mance of the model for prediction of CD-related complications. The time frame for pre-
diction must also be considered. Since the greatest risk of complications occurs within the
first few years after diagnosis, the early reports of long-term risk prediction models that
were developed in this area have become confounded or outdatedwith evolving treatment
strategies, most notably the introduction and widespread use of biologic drugs. For ex-
ample, some models were developed in the pre-biologic era, while others define the need
for thiopurines as advanced disease, but currently thiopurine monotherapy represents a
treatment strategy generally reserved for less severe disease rather than severe disease
[260, 261].
Existing prediction models have been previously described for CD-related outcomes
(summarized in Table 7) which have been limited by selection or referral centre bias, small
sample size, evolving drug treatments and management strategies, long-term time hori-
zons, or broadly inclusive outcome definitions. Nevertheless, it is notable that many of the
items identified as independent predictors have previously been shown to have prognos-
tic value in population-based cohorts with longer-term follow up [1, 3, 81, 141, 144, 262].
Some alternative prediction models have incorporated one or more genetic factors (e.g,
NOD2 risk allele; Table 2.2). In principle, the inclusion of genetic predictors can increase
the prognostic ability of the model [103, 178, 179].
An important clinical concern is how best to risk stratify patients according to disease
severity. This ability may be critical to determine the optimal choice and timing of drug
therapies [263]. These models demonstrate the ability to acceptably discriminate those at
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higher risk of disease-related complications and surgery, and thus who may benefit most
from more intensive management such as early combined immunosuppression, and re-
duce over-treatment and the associated risk of adverse outcomes [260]. Prediction models
can ideally help clinicians to more rapidly identify those at high risk of progression to
severe disease while managing those at low risk with conventional treatment.
A major strength of the study is use of data from large RCT conducted across com-
munity centres, meaning that the endpoints were well-defined and data complete to 24
months of follow up. The pragmatic nature of the trial design meant that consecutive
patients were enrolled, regardless of disease activity, phenotype or treatment and an al-
gorithmof care appliedwhichmirrors clinical practice. Thus, we believe that thesemodels
are generalizable to routine clinical care.
Several limitations should be acknowledged. First, participants in the REACT study
had a longer average duration of disease and the operating characteristics of these models
in newly diagnosed patients remains to be determined. Second, the participants of RE-
ACT were recruited from community clinics which could realistically recruit 60 patients.
Thus, the source population is more reflective of adults living within the catchment areas
of urban community clinics, such as those associated with teaching hospitals and univer-
sities. Third, the performance of the CD-related surgery model performed better than
the complication model, which may be related to using a more well-defined and objective
outcome definition. Fourth, the REACT study did not include biomarkers, serological or
genetic factors and thus these factors could not be incorporated into the current models.
Fifth, the model was validated in the same cohort in which is was developed and thus
independent validation in an external dataset is required. We further opted to use the age
at baseline rather than other models in CD risk prediction which use age at diagnosis. The
reason for this was practical, since age at diagnosis did not show any relationship on risk
prediction and was highly correlated with age at baseline (p = 0.74). While the patient
population tended to be recruited more urban centres, these centres were balanced on CD
caseload (>100 and <100 patients in the practice). It was not possible to investigate the
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distribution of these patients in terms of CD behaviour according to Montréal classifica-
tion, though it is expected that this study population would resemble the average urban
community practice due to continuous enrollment frommay of these centres. However, it
would be unlikely that this study population match either remote and rural populations
or those with severe disease who are referred to specialized clinics.
What follows next are some general remarks and consideration of developing and us-
ing prediction models.
5.2 Additional considerations concerning clustered data
Clustereddata frequently arise in riskmodelling, such as observing individualswithin
families, or patients within clinics. Examples when clustering designs may be used are
when interventions are most appropriately or most feasibly assigned to groups of people,
especially when the investigators are concerned about contamination of the treatment, or
when it is not possible to acquire an individual’s informed consent, such as a trial involving
treatment for acute cardiac arrest or stroke. Patients in the same centre are expected to be
more alike than patients from different centres and patients can no longer be assumed
to be independent. Therefore, it is most appropriate to acknowledge this clustering in
subsequent analyses, including prognostic modelling. This added complexity will also
have direct consequences on model performance.
5.2.1 Modelling choices for cluster randomization designs
Clinical prediction models have traditionally been based on non-hierarchical or flat
designs, thereby ignoring clustering by using standard regression models. Even if clinical
prediction models are developed from clustered data sets, they are scarcely developed
using techniques that explicitly or implicitly take this structure into account.
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Regressions methods for clustered data are needed when one wishes to account for
clustered designs, such as cluster-randomized or multi-centre trials [264]. The two most
popular regression methods for analyzing clustered data are the mixed effect (also called
hierarchical or multilevel) models (more specifically, random intercept models) and gen-
eralized estimating equations (GEEs) (e.g., [265–270]). These models allow for cluster-
specific (conditional) or population-averaged (marginal) interpretations [271]. Another
means of adjusting for clustering could be to fit a GEE or standard logistic model, and
apply a robust variance estimator to account for the clustering effect [272]. Although the
literature on estimation of multi-level methods is quite extensive, issues specific to predic-
tion have been less extensively characterized. This perhaps contributes to the less rapid
adoption of clinical prediction models accounting for clustering.
Accounting for clustering is most important when one is interested in making infer-
ences about the effect size of a variable, since clustering designs can significantly inflate the
standard error. However, the coefficients of each variable will be quite similar when using
standard or mixed-effect models. Thus, for the purposes of prediction of risk at the indi-
vidual level, the standard error is not needed to estimate the individual’s risk. The issue
of clustering in the REACT trial was initially explored by constructing random-intercept
logistic regression models. However, the cluster-specific models agreed closely with the
standard logistic regression models. Therefore, the standard logistic regression models
were preferred.
5.2.2 Options for accounting for clustering
It is not popular to make predictions for individuals using mixed effects models. A
simple approach is to ignore clustering and use standard regression methods. These are
marginalized (population-averaged) predictions. An appeal of this method is that model
performance is primarily based on regression coefficient estimates which are less affected
by clustering effects than are the standard errors. As a result, prediction performance
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should not suffer greatly [257, 273–275]. Another option is to assume an average clus-
ter effect. This can be done in a mixed effects model by setting the random intercept to
its expected value (zero) prior to making predictions, as was done previously [36, 256].
A related option is that the centre-specific (conditional) effect can be estimated from the
outcome prevalence at the new centre [257] or to assume the intercept of a related centre
[276]. These choices may make sense for predictions about patients from very similar or
even the same centre. Lastly, a mixed effects model may be converted to a marginal model
by integrating over the cluster-specific effects to produce marginal predictions analogous
to those from standard regression models [277]. A rebuttal to the approach of using sim-
ple regression is that mixed effects models may be used to derive any other related model,
thus preserving information fidelity and maximizing the potential uses for the model.
5.2.3 When should clustering be taken into account?
Consideration of the level at which predictions are desired and the purpose of the
model are beginning to be emphasized in the literature where clustered observations are
specifically concerned [257, 278]. The investigator and analyst should be forced to consider
whether the scientific question concerns prediction about new individuals or new centres.
If the goal is to implement a predictionmodel at a provincial or national level, then perfor-
mance at that level should be considered. In contrast, when risk models should be used
for decision-making within specific centres, then centre-level performance is of interest. If
the prediction model will be used at a level higher than the cluster, such as implementing
national screening or policy guidelines, then the population-level performance may be of
greater interest. The choice of which type of model to build andwhich type of predictions
to use was recently organized into a proposed decision framework by Wynants and col-
leagues [257]. In this work, they consider model performance using logistic regression on
clustered data [257]. They showed that calibration and discrimination performance can
vary not only as a consequence of over-fitting or under-fitting in the developed model,
but also because of the choice of standard or mixed effects logistic model, and the level at
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which discrimination and calibration are considered (i.e., individual or cluster level) [257].
They find that when the intraclass cluster correlation is low (p < 0.05), a standard logistic
model will strictly be mis-calibrated and have lower discrimination compared to a mixed
effects model, but this difference is negligible. However, the deviations will becomemuch
more serious as the clustering effect grows large (i.e., p > 0.20).
In the context where patients are clustered within hospitals, the ICC is typically be-
low 0.15 [256, 279]. This is certainly the case for the REACT trial [76]. In those cases, the
marginalized predictions will strictly be mis-calibrated but this error will be small with
sufficient events per variable. However, the mis-calibration will become much more seri-
ous as the ICC increases [256, 257, 277, 279]. Marginal prediction models tend to be well
calibrated at the population level butmis-calibrated at the centre level, while mixed effects
models show the opposite trend, particularly for datasets with relatively few observations
[257]. On the other hand, conditional predictions from mixed effects models can be well
calibrated at both levels [257]. When using marginal predictions derived from mixed ef-
fects logistic regression model [277], it is possible to obtain calibrated results [279]. Pre-
dictive performance in clustered data contexts have been assessed at the population level
[279] and also distinguishing between performance at both the population and centre lev-
els [36, 270, 280].
In the specific case of the REACT trial, the focus was on the point estimate for risk,
rather than its variance. Certainly, the degree of clustering was not severe for either CD-
related surgery or complication outcomes (ICC p < 0.05). Simulations under these scenar-
ios showed that the different types of predictions that can be obtained from mixed effects
models yield quite similar results about individual risk compared to standard regression
models [257]. Under these conditions, when only marginal or average centre-specific ef-
fects are assumed, standard and mixed effects models produced similar discrimination
ability at the levels of the population or centre [36, 257]. In other words, the multi-level
model performs reasonably similarly to standard regression models. However, condi-
tional predictions tended to produce superior discrimination at the population-levelwhen
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clustering was greater than 5% and especially when it was more severe [257].
5.3 Final remarks on model building
The model building and predictor selection process is central to the construction of
prediction models as much as any other regression analysis. What follows is a general
overview of methods and concerns as they relate to these issues.
The choice of model is to be informed by the type of outcome available. As previ-
ously mentioned, the two most common outcomes and their corresponding regression
models used in clinical prediction models are to predict binary outcomes using logistic
regression and time-to-event outcomes using Cox proportional hazards regression. In the
REACT dataset, time-to-event data was recorded in days, with a slight bias to experience
events in year one compared to year two. Themain interest from these models was only to
predict whether the outcome would occur in the two year period, as opposed to the time
to the particular event, which was deemed sufficient for informing potential therapeutic
decisions.
5.3.1 Comments on predictor selection and model simplification
Variable selection is just as important a concern for specifying a reasonably correct
model. In the case of the REACT models, predictor selection was informed by a manual
literature search and mainly guided by the judgment of expert gastroenterologists. This
agrees with the approach advocated by Steyerberg [20] and Harrell Jr. [21], for example.
However, muchwork has beendone to develop semi-automatedmethods of variable selec-
tion that try to select the most important variables while limiting bias from trial-and-error
approaches. It is important to remember that selection predictors should still integrate
domain knowledge or expert opinion.
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There is less agreement on whether treatment allocation should be included in the fi-
nal predictive model. Partly related to this choice is whether the prediction question to
be answered is interested in specific effects of treatment, or a marginal effect. Steyerberg
noted that a commonly observed phenomena from clinical trials is that treatment alloca-
tion does have a relatively small effect on outcome, even when statistically significant, in
which case the relevance of other predictors are more important [20]. It was observed in
the REACT models that inclusion of treatment allocation group made a negligible impact
on the prediction and performance of the CD-related surgery model. We also grouped
both treatment arms together to produce a marginal prediction that can more broadly be
applied in different health care settings where intensive therapy may not be economically
feasible, and the specific choice of treatment algorithm may vary, since these are not yet
standardized approaches in the field of gastroenterology.
Harrell [21] favours a backward elimination bootstrap variable selection procedure as
superior to forward selection (of the most significant predictor), backwards elimination
(of the least significant predictor) or step-wise selection methods. In work by Derksen
and Keselmen [281], there was little practical significance on the size of the sample in de-
termining the number of selected variables. Instead, the number of candidate predictors,
and especially the correlation between independent predictors, had a strong influence on
the number of noise variables that enter the model, specifically, the greater the degree of
correlation among true predictors led to increasingly greater fractions of noise variables
being selected as predictors [281]. Overall, they found that noise variables were selected
between 20-74% of the time using these methods.
The bootstrap selection method should in theory correct for bias in variable selection
[282]. The procedure selects any step-wise variable selection method and applies it to a
large number of bootstrap samples (often 500 or 1,000). The frequency with which each
variable was selected in the resulting models is tabulated and a model composed of the
most frequently selected variables by the selection procedure is built. The correlation
among candidate predictors is then examined and the redundant variables may be re-
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moved. The final model is then selected based on the conditional relative frequency of
the remaining variables. The bootstrap method is advantageous where there are large
numbers of noise variables [282] yet can fail when there is a high degree of correlation
among candidate predictors (i.e., in situations of multicollinearity). The latter problem
of collinearity is a limitation of stepwise variable selection in general, and is not limited
to just bootstrap methods. When there are no clear patterns in the resulting set of cho-
sen predictors, the final choice of the model still requires external criteria such as expert
knowledge, model simplification or shrinkage.
There are severalmethods ofmodel simplification by removing or shrinking irrelevant
predictors. Linear shrinkage of predictors has already been discussed in the context of the
REACTmodels. Harrell has suggested using a step-down approach [21] in which the pre-
dictors that have the weakest relationship with the linear predictor are removed and the
smaller, remaining model reasonably approximates the full model. One advantage to this
approach is that reportedly avoids over-fitting since any penalization that has been ap-
plied remains in the linear predictor [21]. Similarly, the backwards elimination approach
is guided by a rule that drops variables if they fail to reach a significance threshold (often
α = 0.05 or 0.10). This process occurs iteratively until there are no more non-significant
variables to remove [283]. A third method would be to focus on optimizing the Akaike in-
formation criterion (AIC). The step-down and backwards elimination approaches tended
to produce similarly performing models (based on both the c-statistic and Brier score)
when themodel included some irrelevant predictors [283]. However, model simplification
based on the AICwas a successful strategy, regardless of the above simplificationmethods
[283]. This was desirable because it sometimes producedmodels that performed even bet-
ter than the full model and its ease of application [283, 284]. Some conditions of the AIC
stopping rule are that the model and predictors should be fully pre-specified and that the
method works best when the models considered are "nested" (subsets of a larger model)
[285]. However, when the number of observations is small, the risk of over-fitting and
extreme bias in variable selection is high. Here, step-wise methods are to be avoided in
favour of using expert knowledge or developing full models and employing somemethod
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of shrinkage of the coefficients by penalized regression [30, 38, 43, 68, 284].
5.3.2 When should a prediction model be used?
Presume for this discussion that the hypothetical clinical prediction model has been
validated and shows favourable performance characteristics. When such a model is avail-
able, what are the barriers to their use? The most common reasons that clinical prediction
models are not used are because clinicians are either unaware of their existence or that they
are unsure of how to take advantage of such models [286, 287]. The former is remedied by
education, but the latter requires implicit trust in the modelling process and preferably to
understand the workings of the model. For these reasons, traditional regression models
are still preferred to data-driven approaches such as artificial neural networks and classi-
fication and regression trees, despite no clear superiority of any one modelling technique
[286, 287]. Several other barriers to use have been discussed in the literature, including
model performance that is not superior to clinical judgment or care-as-usual, the clinician
did not fully adhere to the (changes in) risk-dependent decisions, or increased attention
to the risk prediction may lead to increased treatment rather than as a result of increased
need for treatment (i.e., a Hawthorne effect) [288].
The advantage of using a predictive model is to produce a risk estimate or suggest a
decision that is tailored to the individual and thereby offering better riskmanagement and
avoiding unnecessary investigations or diagnostics [27]. However, it is not enough just to
validate a clinical prediction model. Ideally, two conditions must be met for successful
adoption of prediction rules. First, the clinician behaviour must be modified to use the
model as a decision aid. Second, the model must accurately differentiate patients with
and without the disease or outcome so that there is measurable benefit to patient care.
In this way, the model complements the clinician’s skill and abilities, the patient benefits
from better risk management, naturally leading to better cost-effectiveness.
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When a candidate model is produced, if the clinician is the intended user, it is worth
considering whether the model can augment their own diagnostic or prognostic abilities.
There is some evidence from systematic reviews andmeta-analyses to suggest that clinical
judgment can be just as sensitive as the model to diagnose the disease state, yet the mod-
els may have superior specificity [289, 290]. In other words, no more cases would have
been identified by using a prediction model, yet using the model could reduce the need
for potentially time-consuming, expensive or invasive diagnostic testing in order to rule
out disease. Some clinical prediction models have been tested in formal impact assess-
ments in which aided clinical management had superior performance to management by
clinical judgment alone. For example, the bacterial pneumonia score was tested against
the unaided clinician’s judgment [291]. The group managed according to the risk predic-
tion model used significantly less antibiotics and did not experience increased treatment
failure [291]. The use of the Padua prediction score, assessing the risk of venous throm-
boembolism in hospitalized patients, was also superior to clinical judgment alone [292]. In
contrast, there are some outcomes in which a predictionmodel can inform risk-dependent
treatment strategies to achieve better patient care. One example is the use of model for
postoperative nausea and vomiting in which low-risk patients can reasonably be man-
aged by usual care, whereas high-risk patients benefit frommanagement according to the
model [288]. There is still much room to provide clinicians with decision support tools.
However, the decision of whether or not to implement such models are best decided in
a head-to-head controlled trial to determine if the aided clinical judgment performs bet-
ter than clinical expertise alone and should also account for the relative harms or costs of
misclassification errors.
5.4 Conclusion
In summary, we have developed and validated clinical prediction models for CD-
related surgery and complications using data from a large, pragmatic RCT, with good
overall performance for predicting the outcome of surgery within 24 months. We have
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transformed these models into scoring tools facilitating their use in the clinic and these
now require external validation.
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